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DEFINITION OF TERMINOLOGY 
 
Terms referred to in this investigation are explained and extended on in the 
following paragraphs: 
 
Antithyroid drug: A substance that inhibits the synthesis of thyroid 
hormones and can be used in the treatment of Graves’ disease (Anderson 
1998:109). There is a variety of antithyroid drugs including thioamides, such 
as propylthiouracil and methimazole. Antithyroid drugs are also used to 
control hyperthyroidism during awaiting remission and before a 
thyroidectomy. 
 
Beta rays: Atoms of disintegrating radioactive elements emits a stream of 
beta particles. This stream of beta particles is known as beta rays (Anderson 
1998:186). 
 
Euthyroid: A normal functioning thyroid gland (Anderson 1998:595). 
 
Gamma rays: During a nuclear disintegration emitted from the nucleus of an 
atom is electromagnetic radiation of a short wavelength (Anderson 1998:672). 
Gamma rays travel at the speed of light and lack mass and electric charge. 
 
Goitre: Swelling of the neck area associated with an enlarged thyroid gland 
(Anderson 1998:702). The cause of this enlarged thyroid gland can be linked 
to hyperthyroidism, hypothyroidism and even normal levels of thyroid function. 
The appearance of the goitre may be cystic or fibrous, containing a number of 
follicles or nodules.  
 
Graves’ disease: It is an autoimmune disease of unknown origin and there is 
evidence that it is familial (Anderson 1998:712). In more that 60% of patients 
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with Graves’ disease antibodies to thyroglobulin or thyroid microsomes are 
found. 
 
Hyperthyroidism: It is mainly associated with hyperactivity of the thyroid 
gland (Anderson 1998:795). The metabolic processes of the body are 
accelerated with hyperthyroidism and the thyroid gland is enlarged with the 
secretion of greater than normal amounts of thyroid hormones. 
 
Hypothyroidism: This is a thyroid state resembling thyroid deficiency, with 
decreased activity in the thyroid gland (Anderson 1998:803). 
 
Iodide: The substance is an anion of iodine (Anderson 1998:871). The salts 
most commonly used in medications are potassium iodide and sodium iodide. 
 
Iodine: Iodine has an atomic mass of 126.90 and an atomic number of 53 
(Anderson 1998:871). This non-metallic element falls within the halogen 
group. Iodine is present in the thyroid gland in the human body, mostly in the 
form of thyroglobulin. In the human body where it is deficient, it can result in 
goitre or cretinism. 
 
Myxoedema: The most rigorous form of hypothyroidism (Anderson 
1998:1075). 
 
Organification: It is a process that occurs within the thyroid gland in which 
iodide is oxidised and integrated into tyrosyl residues of thyroglobulin 
(Anderson 1998:1156). Through the enzyme thyroid peroxidase the process 
of organification is catalysed. 
 
Radioactive iodine: A radionuclide of iodine, used as a tracer in medicine 
and biology (Anderson 1998:1378). 
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Radioactive iodine uptake test: It is the administration of a tracer dosage of 
RAI orally in a test of thyroid function where the thyroid absorbs and 
incorporates the RAI (Anderson 1998:1378). This uptake of iodine by the 
thyroid is then measured by a probe to indicate the uptake percentage by the 
thyroid gland. 
 
Thyroidectomy: A surgical procedure in which the thyroid gland is removed 
(Anderson 1998:1616). 
 
Thyroid gland: An organ of high vascular origin that can be found in the 
region of the front neck area (Anderson 1998:1616). The thyroid gland weighs 
about 30g and consists of two lobes connected in the middle by the isthmus. 
 
Thyroid hormone: The thyroid gland secretes an iodine containing 
compound mostly known as T4 and in smaller amounts T3 (Anderson 
1998:1617). T4 and T3 have various abilities and functions in the human body, 
for example increasing the rate of metabolism; affecting body temperature; 
regulating protein, fat and carbohydrate catabolism in all the cells; skeletal 
maturation; sustaining growth hormone secretion, cardiac rate, force and 
output; supporting the central nervous system (CNS) development; and 
stimulating the synthesis of many enzymes. They are, in addition, needed for 
muscle tone and vigour. 
 
Thyroid-stimulating hormone (TSH): A secreted substance from the 
anterior lobe of the pituitary gland directs the release of thyroid hormones 
(Anderson 1998:1617). TSH is essential for the growth and function of the 
thyroid gland. TSH secretion in turn is regulated by the thyrotropin-releasing 
factor present in the region of the median eminence of the hypothalamus. The 
normal levels present in the blood are two to 10 milliunits per litre (mU/l). 
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Thyroid storm: Medical emergency of uncontrollable hyperthyroidism caused 
by a release of increased amounts of thyroid hormones into the bloodstream 
(Anderson 1998:1617). The cause of this thyroid condition may be 
spontaneous, stress, infection or by a thyroidectomy performed on a patient 
who is inadequately prepared with antithyroid drugs. 
 
Thyroxine (T4): It is derived from tyrosine and is a hormone of the thyroid 
gland that influences the metabolic rate (Anderson 1998:1618). 
 
Triiodothyronine (T3): It is a hormone of the pituitary gland. T3 has various 
functions in the human body, for example helping to regulate growth and 
development; helping to control metabolism and body temperature; and by a 
negative-feedback mechanism, acting to inhibit the secretion of thyrotropin by 
the pituitary gland (Anderson 1998:1654). T3 is produced in the peripheral 
tissues, but is also synthesised and stored in the thyroid gland as amino acid 
residue of the protein thyroglobulin. The normal value present in the blood of 
an adult is 110 to 230 nanogram per decilitre (ng/dl).  
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SUMMARY 
 
Key terms: radioactive iodine uptake; 24-hour iodine-131 uptake; Graves’ 
disease; 6-hour iodine-131 uptake; thyroid; therapeutic dosage  
 
In the South African Health Services (SAHS) it is each health worker’s 
responsibility to find ways to reduce health care cost and improve health 
service to the public. The measurement of radioactive iodine uptake (RAIU) 
by the thyroid gland for diagnostic purposes has been used as early as the 
1940s. The 24-hour (hr) iodine-131 (131I) uptake measurement is traditionally 
used for the calculation of the 131I administered activity for therapy dosage. 
This entails that the patient’s hospitalisation is prolonged, which increases the 
costs. The literature also indicates that the 24-hr 131I uptake value can be 
discarded and only the 6-hr 131I uptake measurement is needed to calculate 
administered activity for therapeutic dosages for Graves’ patients. Therefore, 
if it can be confirmed that the 6-hr 131I uptake measurement alone is needed, 
the SAHS could decrease hospitalisation costs.  
 
The overall goal of the investigation was to analyse the 6-hr and 24-hr 131I 
uptake measurements of patients with Graves’ disease at the Universitas 
Hospital. The aim was to determine the relationship between the 6-hr and 24-
hr RAIU values to establish the therapeutic dosage for Graves’ disease. 
 
To achieve the aim, three objectives were set. First, to serve as a background 
to the investigation, a literature survey relating to the RAIU measurements of 
patients with Graves’ disease was made. Second, a retrospective analysis 
was performed by collecting the 6-hr and 24-hr 131I uptake measurements of 
patients with proven Graves’ disease at the Universitas Nuclear Medicine 
Department (UNMD). Finally, the data obtained from the retrospective 
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analysis was analysed, summarised and compared to answer the 
investigation questions. 
 
The investigation group included patients with confirmed Graves’ disease 
who had undergone both the 6- and 24-hr 131I RAIU at the Universitas 
Hospital from the beginning of 2004 to the end of 2005. Graves’ disease is 
confirmed by the following factors at the UNMD, namely: Suppressed TSH, 
elevated T4 and T3 values, an increased uptake on the 99mTc-pertechnetate 
scan and increased 6- and 24-hr 131I RAIU values. The UNMD statistics show 
that 178 patients were diagnosed with Graves’ disease during this period. 
The patients of the investigation group included both male and female 
patients from different races, ranging from 15-75 years. In order to increase 
the validity of the investigation, all factors that could influence the accuracy of 
the 131I thyroid uptake test were excluded. After the exclusion and inclusion 
criteria had been applied, the final investigation group was made up of 124 
Graves’ disease patients. 
 
The data obtained from the patient files was noted on the different data 
sheets (see Appendix A) for further analysis. The information from these data 
sheets was then used to obtain the investigation results. The Department of 
Biostatistics of the University of the Free State (UFS) was consulted for 
recommendations regarding the management of data and the processing of 
results. All values were summarised by means and Standard Deviations (SD) 
or percentiles. Mean or median differences were calculated with a 95% 
Confidence Interval (CI). A regression analysis was made between the 6-hr 
and 24-hr 131I RAIU values.   
 
The highest RAIU value is the best to calculate the therapeutic dosage, as 
this gives a true reflection of the thyroid function of a Graves’ disease patient. 
In the investigation group the median of the 24-hr 131I RAIU values was higher 
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than the 6-hr 131I RAIU values. The findings showed that the 24-hr 131I RAIU 
in most of the investigation group was the highest value and most effective to 
calculate the 131I therapeutic dosage. 
 
At a time when research-based practice is taking on an increasingly important 
role, it is essential for nuclear medicine departments to make evidence-based 
recommendations. This investigation found that the correlation between the 
6-hr and 24-hr RAIU clearly justified the cost spent on Graves’ disease 
patients who must stay overnight for the 24-hr 131I RAIU procedure.  
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SAMEVATTING 
 
Sleutelterme: Radioaktiewe jodiumopname; 24-uur-jodium-131-opname; 
Graves se siekte; 6-uur-jodium-131-opname; skildklier; terapeutiese dosis 
 
In die Suid-Afrikaanse Gesondheidsdienste (SAGD) is dit elke 
gesondheidswerker se verantwoordelikheid om wyses te vind om 
gesondheidsdienste se uitgawes te verlaag en om gesondheidsdienste aan 
die publiek te verbeter. Die meting van die radioaktiewe jodiumopname 
(RAJO) van die skildklier vir diagnostiese doeleindes is al sedert die 1940’s in 
gebruik. Die opnamewaarde van die 24-uur-jodium-131 (131I) is tradisioneel 
gebruik vir die berekening van die toedieningsaktiwiteit van die 131I vir die 
terapeutiese dosis. Dit behels dat die pasiënte se hospitalisasie verleng moet 
word en die uitgawe daaraan verbonde, verhoog word. Die literatuurstudie 
het ook aangedui dat die 24-uur-131I-opnamewaarde geïgnoreer kan word en 
dat slegs die 6-uur-131I-opnamewaarde nodig is vir die berekening van die 
toedieningsaktiwiteit vir die terapeutiese dosis vir ‘n pasiënt met Graves se 
siekte. As dit gevolglik bevestig kan word dat die 6-uur-131I-opnamewaarde 
alleen nodig is, dan kan die SAGD se uitgawes van hospitalisasie verlaag 
word. 
 
Die algehele doel van die ondersoek was die analise van die 6- en 24-uur-
131I-opnamewaardes van pasiënte met Graves se siekte by die Universitas 
Hospitaal. Die doel was om te bepaal wat die verhouding tussen die 6- en 24-
uur-RAJO-waardes is om te beslis wat die terapeutiese dosis vir Graves se 
siekte is.  
 
Om die doel te bepaal, is drie doelstellings gevolg. Eerstens, om te dien as 
agtergrond tot die ondersoek, is ‘n literatuurstudie met betrekking tot die 
RAJO-waardes van pasiënte met Graves se siekte gedoen. Tweedens is ‘n 
 xxxi
retrospektiewe analise gedoen deur die versameling van die 6-uur- en 24-
uur-131I-opnamewaardes van pasiënte met bevestigde Graves se siekte by 
die Universitas Kerngeneeskundige Departement (UKGD). Laastens is die 
data wat versamel is vir die retrospektiewe analise geanaliseer, opgesom en 
vergelyk vir antwoorde tot die ondersoekvrae. 
 
Die ondersoekgroep sluit pasiënte in met bevestigde Graves se siekte wat 
gegaan het vir beide ‘n 6- en 24-uur-131I-RAJO by die Universitas Hospitaal 
vanaf die begin van 2004 tot die einde van 2005. Graves se siekte is bevestig 
deur die volgende faktore by die UKGD, naamlik: onderdrukte TSH; 
verhoogde T4- en T3-waardes, ‘n verhoogde opname op die 99mTc-
pertechnetaatondersoek en ‘n verhoogde 6- en 24-uur-131I-RAJO-waardes. 
Die UKGD-statistiek wys dat 178 pasiënte gediagnoseer is met Graves se 
siekte gedurende hierdie periode. Die pasiënte vir die ondersoekgroep het 
beide manlike en vroulike pasiënte van verskillende rasse tussen 15-75 jaar 
ingesluit. Met die doel om die geldigheid van die ondersoek te verhoog, is alle 
faktore wat die akkuraatheid van die 131I-skildklieropnametoets beïnvloed, 
uitgesluit. Na die uitsluitings- en insluitskriteria toegepas is, het die finale 
ondersoekgroep uit 124 pasiënte met Graves se siekte bestaan. 
 
Die data versamel uit die pasiëntlêers is aangedui op verskillende datablaaie 
vir verdere analise (kyk Bylae A). Die inligting vir hierdie datablaaie is daarna 
gebruik vir die ondersoekresultate. Die Departement van Biostatistiek van die 
Universiteit van die Vrystaat (UV) is genader vir aanbevelings in verband met 
die bestuur van data en die prosessering van resultate. Alle waardes is 
opgesom deur gemiddelde en Standaard deviasie of presentiele. Die gemene 
of mediaanlyn van verskille is bereken met ‘n 95% Vertrouensinterval (VI). ‘n 
Regressie-analise is gemaak tussen die 6-uur- en 24-uur-131I-RAJO-waardes. 
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Die hoogste RAJO-waarde is die beste vir die berekening van die 
terapeutiese dosis, omdat dit ‘n ware refleksie gee van die skildklierfunksie 
van ‘n pasiënt met Graves se siekte. Die ondersoekgroep se gemiddelde 24-
uur-131I-RAJO-waarde was hoër as die gemiddelde 6-uur-131I-RAJO-waardes. 
Die bevinding dui daarop dat die 24-uur-131I-RAJO in die meeste van die 
ondersoekgroep die hoogste was en mees effektief is vir die berekening van 
die 131I terapeutiese dosis. 
 
In ‘n tyd wanneer navorsingsgebaseerde praktyk ‘n toenemende belangrike 
rol speel, is dit noodsaaklik vir kerngeneeskundige departemente om 
getuienis-gebaseerde aanbevelings te maak. Die ondersoek het gevind dat 
die verband tussen die 6-uur en 24-uur duidelik die uitgawes regverdig wat 
spandeer word om pasiënte met Graves se siekte te laat oornag vir die 24-
uur-131I-RAJO-prosedure. 
 
 
 
 
 
  
 
 
CHAPTER 1 
 
 
ORIENTATION TO THE INVESTIGATION 
 
 
1.1 INTRODUCTION 
 
The measurement of radioactive iodine uptake (RAIU) by the thyroid gland for 
diagnostic purposes has been used as early as the 1940s (Hayes, Akre & 
Gorman 1990:519). This technique has been used worldwide in the 
assessment of thyroid function and in thyroid diagnostic testing (Braunwald, 
Isselbacher, Petersdorf, Wilson, Martin & Fauci 1987:1736). RAIU of the 
thyroid not only reflects the early phase of thyroid hormonegenesis, but also 
reveals information about the overall function of the thyroid gland (Early & 
Sodee 1995:627). RAIU could provide additional information with regard to 
hyperthyroidism, euthyroidism and hypothyroidism (Hayes et al. 1990:519). In 
addition, RAIU value is used to accurately calculate the iodine-131 (131I) 
treatment dosages for patients with hyperthyroidism.  
 
The correct calculation of the radioactive iodine (RAI) treatment dosage is 
important to prevent undertreatment and possible recurrence of disease. The 
24-hour (hr) 131I uptake values are traditionally used to calculate the 
therapeutic dosage (Braunwald et al. 1987:1736). This entails that the 
patient’s hospitalisation may be prolonged resulting in an increase in health 
care costs. Hayes et al. (1990:519) suggested that the 24-hr 131I uptake value 
can be discarded and that the 6-hr 131I uptake value alone could be used to 
calculate the therapeutic dosage. In the South African Health Services 
(SAHS) it is each health worker’s responsibility to find ways to reduce health 
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care cost and improve health service to the public.  Yet, if it could be 
confirmed that the 6-hr 131I uptake value of a Graves’ disease patient alone 
can be used, the SAHS could decrease the cost. With these considerations in 
mind a brief overview of relevant physiological and clinical factors associated 
with Graves’ disease is indicated. 
 
1.1.1 Formation and secretion of thyroid hormones 
Ganong (1995:291) states that the main hormones secreted by the thyroid 
are triiodothyronine (T3) and thyroxine (T4) (Kasper, Fauci, Longo, Braunwald, 
Hauser & Jameson 2005:2104). These hormones are iodine-containing 
amino acids. T3 and T4 are synthesised by iodination and condensation of 
tyrosine molecules in the colloid, bound by peptide linkage with thyroglobulin. 
T3 is especially formed in the peripheral tissues by deiodination of T4. Other 
compounds like mono-iodotyrosine and reverse triiodothyronine (RT3) are 
also found in the thyroid venous blood. RT3 is inactive, whereas T3 is more 
active than T4. The thyroid cells thus have three main functions, namely first 
to transport and collect iodine from the circulation, second, to synthesise T3 
and T4 and store them in the colloid and, last, to remove the thyroid hormones 
from thyroglobulin and secrete the thyroid hormones into the circulation, the 
latter regulated by pituitary secreted thyroid-stimulating hormone (TSH) 
through a negative feedback mechanism. 
 
1.1.2 Clinical correlation 
Ganong (1995:300) further indicates that the signs, symptoms and 
complications of both hypothyroidism and hyperthyroidism in humans are a 
predictable consequence of the physiological effects of thyroid hormones or 
the lack thereof. Graves’ disease is an autoimmune disease of the thyroid 
gland in which T-lymphocytes (T-cells) activated by antigens stimulate the B-
lymphocytes (B-cells) to produce circulating antibodies against these antigens 
(Ganong 1995:301).  
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A patient with Graves’ disease may have a diffuse goitre, pretibial 
myxoedema and ophthalmopathy, but over 50% of these patients do not 
present with all these signs (Freitas 1999:297). Therefore, Graves’ disease is 
confirmed biochemically by a suppressed serum TSH [<0.05 millilitre units per 
litre (mIU/l)] and elevated free T4 or T3 levels (Freitas 1999:297-298). The 
difference in biochemistry between hyperthyroidism and hypothyroidism as 
different clinical states is provided in Table 1.1. 
  
Table 1.1:  The difference in biochemistry between hyperthyroidism 
and hypothyroidism 
Clinical state Concentrations 
of Binding Pro-
teins 
Total 
Plasma T4, 
T3, RT3 
Free 
Plasma T4, 
T3, RT3 
Plasma 
TSH 
Hyperthyroidism Normal High High Low 
Hypothyroidism Normal Low Low High 
Source: Ganong (1995:295) 
 
Graves’ disease is best differentiated from other thyrotoxic entities by a 
thorough clinical history and examination. These examinations include a 
Technetium-99-metastable-pertechnetate (99mTc-pertechnetate) thyroid scan 
to confirm a diffuse enlarged gland with homogeneous increased uptake and 
an increased 24-hr 131I RAIU value provide diagnostic information about the 
thyroid gland of a Graves’ disease patient (Kasper et al. 2005:2115) (Freitas 
1999:298). 
 
1.1.3 Hormone measurement 
Different diagnostic tests are necessary in order to distinguish Graves’ 
disease from single toxic nodule and toxic multinodular goitre, as well as 
iodine induced hyperthyroidism (McDougall 1991:81). These tests include 
clinical evaluation, biochemical measurements, RAIU and scintigraphy of the 
thyroid. Laboratory methods (in vitro tests) of the thyroid hormones give an 
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indication of thyroid function (Early & Sodee 1995:623). Graves’ disease has 
increased levels of thyroid hormones because of the increased synthesis and 
secretion of these hormones (Harbert & Da Rocha 1984:30; Kasper et al. 
2005:2115). Graves’ disease can thus be confirmed, among others, by 
biochemical tests that include the in vitro measurement of the thyroid 
hormones T4, T3 and TSH (McDougall 1991:92). 
 
The normal range for T4 is 4.7-11 microgram per decilitre (µg/dl) and for TSH 
5-25 microunits (µU) after injection of 400 to 500 microgram (µg) of thyroid-
releasing hormone (TRH) (Kaplan 1985:871; Kasper et al. 2005:2108). 
Graves’ patients’ laboratory tests usually show an increased serum T4 or 
serum T3, reduced TSH and increased RAIU values (Braunwald et al. 
1987:1744). Therefore, both T4 and RAIU have abnormally increased levels in 
a Graves’ disease patient. As T4 and RAIU values confirm the diagnosis for 
Graves’ disease it would be interesting to see if there is a correlation between 
the values of the thyroid hormones and RAIU (see Appendix A:1).  
 
Laboratory tests of thyroid hormones such as TSH give an indication of 
thyroid function (Early & Sodee 1995:623). Harbert and Da Rocha (1984:35) 
confirm that a good indicator of thyroid hormone production will always be 
TSH. In Graves’ patients TSH concentrations are below 0.05 microunits per 
millilitre (µU/ml) (Early & Sodee 1995:625). Laboratory tests demonstrate the 
physiological function of the thyroid hormones, but the 131I thyroid uptake 
technique demonstrates the organification and uptake of 131I  in the thyroid 
gland. The next section will concentrate on the 131I  thyroid uptake technique.   
 
1.1.4   131I thyroid uptake technique 
The 131I thyroid uptake technique described by the International Atomic 
Energy Association (IAEA) was developed to standardise RAIU worldwide. 
The prerequisites includes the following (IAEA 1961:536-538): 
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    The probe to be used should have a sodium iodide-thallium [NaI(Tl)] 
crystal size of not less than 2.5 x 2.5 centimetre (cm).  
    The thyroid-to-crystal distance should be between 20 and 30 cm (it 
should always be kept at a fixed distance).  
    The perspex neck phantom should be cylindrical in shape.  
     The phantom diameter calculation is 15 cm and 15 cm in height and 
the distance from the edge of the phantom to the surface of the hole 
should be 0.5 cm.  
     The patient dosage capsules as well as the standard for the quality 
control are placed in the neck phantom that corrects for attenuation by 
simulating the thickness of neck structures.  
     The capsules used for the 131I RAIU standard are dissolved in 30 
millilitre (ml) of hot water and then inserted into the neck phantom. 
Both the patient’s dosage capsules and the standard for the quality 
control are counted at a similar distance from the probe as to be used 
when the patient will be counted.  
    The 131I capsules given to the patient are orally administered.  
 At the UNMD the decay factor is provided for in the computer 
programme used to automatically calculate the RAIU value. The 
counts per minute (CPM) are obtained and thyroid uptake value as 
pointed out by Datz (1993:6) is calculated as follows (also see 
Appendix B:4):                 
Percentage (%) Uptake =                      CPM Thyroid x 100   
                                                  
 CPM dosage administered x decay factor 
    
1.1.5 Normal values for RAIU 
No single figure (range) can be accepted for a normal 24-hr RAIU value, 
because there is a wide regional disparity in dietary iodine (Bernier, Christian 
& Langan 1994:233). It is thus advisable that nuclear medicine departments 
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should establish their own physiologic range for RAIU values. Bernier et al. 
(1994:233) indicate that RAIU values below 12% are considered low and 
above 35% increased. At the Universitas Hospital Nuclear Medicine 
Department (UNMD) a 131I RAIU value range between 10-35% is considered 
to be normal (the normal range UNMD was considered due to the Free State 
dietary iodine intake).        
   
1.1.6 Factors influencing RAIU  
The 131I RAIU uptake value is influenced by a variety of medications and 
substances that can lower the uptake of iodine (Becker, Charkes, Hurley, 
McDougall, Price, Royal, Sarkar & Dworkin 2003:35) (see Appendix C:5). 
Therefore, the medication history of the patient is of great importance and 
efforts should be made to ensure that the patient is not ingesting iodine 
containing materials, thyroid hormone or antithyroid drugs, all of which can 
influence the RAIU value. Other causes of iodine contamination should also 
be excluded, for example iodine containing X-ray contrast media. 
 
1.1.7  The ideal radionuclide for uptake and measurement 
There are various radionuclides that can be used for uptake and 
measurement in the thyroid gland. These radionuclides include iodine-123 
(123I), iodine-124 (124I), 99mTc-pertechnetate and 131I. 123I is not preferred for 
RAIU measurements, because of the short half-life (13 hours), presence of 
long-lived impurities, especially high-energy 124I, associated with down-scatter 
problems (Datz 1993:5). 123I is also very expensive and not always available 
(Bernier et al. 1994:231). 99mTc-pertechnetate can be used for thyroid imaging 
and is advantageous because of its low cost, ready availability, low radiation 
exposure and high-quality imaging (Wagner, Szabo & Buchanan 1995:599). 
99mTc-pertechnetate is not organified in the thyroid gland and does not 
provide adequate thyroid functional uptake information. 99mTc-pertechnetate 
also has other characteristics that make it unsuitable for thyroid uptake 
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testing, including the low absolute uptake of pertechnetate; high neck 
background; and the activity in the neck area which constantly changes 
because of the biodistribution of pertechnetate. 131I is used mostly for thyroid 
uptake measurement values, even though it has a high radiation dosage 
(Wagner et al. 1995:598). Since it is organified in the thyroid, it is made ideal 
for thyroid functional testing.  
 
The administered activity recommended by the IAEA (1961:535) for 131I 
uptake measurement should not exceed 0.37 megabequerel (MBq) 131I. The 
radiation exposure for 131I to the thyroid is very high, namely 0.27-0.54 gray 
per megabequerel (Gy/MBq). At the UNMD the dosage used for the 131I 
uptake measurements is between 0.30 and 0.37 MBq, which still falls within 
the IAEA recommendations. 
 
1.1.8 131I therapeutic treatment of Graves’ disease 
The first RAI therapy for Graves’ disease was administered by Hertz and 
Roberts in the early 1940s (Freitas 1999:297). Nordyke and Gilbert 
(1991:411) also indicated that in the early years of dosage calculation 
measurement, mathematical formulas involving thyroid uptake, estimated 
gland size and tracer retention, were used. This approach met with several 
major failures, since it is difficult to estimate the thyroid weight (size) by 
palpation, even when done consistently by the same person (Nordyke & 
Gilbert 1991:414). There are various therapeutic options to treat Graves’ 
disease, including thionamide drug therapy (Kasper et al. 2005:2115), 
subtotal thyroidectomy and RAI (De Bruin, Croon, De Klerk & Van Isselt 
1994:507). According to De Bruin et al. (1994:507-508), RAI became the best 
treatment option for Graves’ disease, since it is easy to use and safe. RAI is 
also used to treat Graves’ disease at the UNMD. The calculation of the 
correct therapeutic administration activity for Graves’ disease is important, 
since the destruction of thyroid follicular cells by RAI to a large extent 
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depends on the amount of 131I activity absorbed. 131I RAIU should thus be 
performed to (i) confirm the diagnosis of Graves’ disease; and (ii) to calculate 
the administration activity for therapeutic dosage. 
 
A 131I administration activity of sufficient quantity to induce relief of 
hyperthyroidism by beta particle irradiation of follicular cells must be 
calculated for a Graves’ disease patient (Freitas 1999:302). The result will be 
cellular necrosis or affective deoxyribosenucleic acid (DNA) damage to 
surviving cells to reduce the overproduction of thyroid hormones (prevent 
replication of cells causing Graves’ disease).  
 
Dworkin, Meier and Kaplan (1995:212) state that most of the patients 
receiving 131I for Graves’ disease eventually become hypothyroid (due to the 
basic pathophysiology of Graves’ disease). Patients treated with moderate 
administered therapeutic dosage activity of 131I have an incidence of 50% for 
developing hypothyroidism within 10 years (Maisey, Britton & Gilday 
1991:209; Kasper et al. 2005:2116). Treatment success of Graves’ disease is 
reduced with smaller 131I administration activity, as well as the risk of 
developing hypothyroidism. Therefore, a small 131I administration activity will 
delay the development of hypothyroidism, but - on the other hand - may 
cause more relapses of Graves’ disease (Riccabona 1994:12). Since Graves’ 
disease patients in many cases end up with hypothyroidism, those patients 
receiving 131I therapy should be monitored for further treatment. The 
development of hypothyroidism induced by 131I administration activity after 
Graves’ disease requires lifelong thyroxine therapy. 
 
1.1.9  Adequate absorbed activity for the intrathyroid tissue 
The calculation of the correct therapeutic dosage for Graves’ disease is 
important, since the destruction of thyroid follicular cells by RAI to a large 
extent depends on the dosage of 131I absorbed (De Bruin et al. 1994:508). 
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Maisey et al. (1991:209) state that a large single 131I administration dosage, 
for example 555 MBq 131I, has a high cure rate for hyperthyroidism and 
prevents return of Graves’ disease. On the other hand, according to 
Alexander and Larsen (2002:1073), an absorbed activity of 296 MBq 131I in 
the thyroid is an effective treatment for most patients with Graves’ disease. 
The UNMD uses the RAIU for the calculation of the 131I therapeutic dosage 
for Graves’ patients so that the intrathyroid absorbed activity (IAA) received is 
296 MBq 131I. The ranges of 131I absorbed activity per gram (g) of thyroid 
tissue for the effective treatment of Graves’ disease as given by the European 
Association of Nuclear Medicine (EANM) (2003:30) is from 2.2-3.0 MBq/g up 
to 6.0-7.0 MBq/g. Hence, for a thyroid weighing 50g, the 131I therapeutic 
dosage should be between 110 MBq and 350 MBq for the effective treatment 
of Graves’ disease. A Graves’ disease patient who receives an IAA of more 
than 350 MBq, consequently has received unnecessary 131I therapeutic 
activity to the thyroid gland. A Graves’ disease patient who receives an IAA of 
more than 350 MBq is considered by the UNMD to have received a less 
accurate therapeutic dosage. Therefore, when calculating the different 
therapeutic dosages with the 6-hr 131I RAIU value or the 24-hr 131I RAIU 
value, the IAA should not be more than 350 MBq of 131I, otherwise the patient 
will receive unnecessary 131I activity to the thyroid gland. 
 
In a normal person who received 131I orally to determine RAIU value, the 
measured uptake increases gradually and then reaches a plateau between 
18- and 24-hr after intake (Harbert & Da Rocha 1984:9). Van Isselt, De Klerk, 
Koppeschaar and Van Rijk (2000:609) indicated that the 24-hr 131I RAIU 
value is traditionally used for the calculation of the 131I administration activity 
for therapeutic dosage. According to these authors, the 24-hr 131I RAIU value 
is most effective for the calculation of the administration activity (CAA) for 
patients with Graves’ disease (Van Isselt et al. 2000:609). Wagner et al. 
(1995:598) also suggest that the 24-hr 131I uptake value is highly 
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recommended for treatment of Graves’ disease. The 24-hr 131I RAIU value is 
therefore the favourite choice for therapeutic dosage calculations. The reason 
why 24-hr 131I RAIU value is preferred is that rapid turnover of 131I in the first 
two hours and a lower 24-hr RAIU value in Graves’ disease are supposed to 
be rare (Harbert & Da Rocha 1984:12). Yet, Graves’ disease 
(hyperthyroidism) can show different characteristic curves and turnover points 
of thyroid uptake after 131I oral administration (see Figure 1.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The different characteristic curves of thyroid uptake of 131I 
after oral administration (courtesy of Harbert & Da Rocha 
1984:12.) 
 
The highest thyroid uptake value is the optimal value to calculate the effective 
and accurate therapeutic dosage calculation (Harbert & Da Rocha 1984:12). 
The 24-hr RAIU value is usually higher than the 6-hr RAIU value in Graves’ 
disease, therefore the 24-hr RAIU value is regarded as the better choice for 
therapeutic dosage calculation. The transit patterns of the 6-hr and 24-hr 131I 
RAIU values need to be investigated to see if the 24-hr RAIU in Graves’ 
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disease patients at the UNMD is the higher RAIU value and most effective to 
calculate 131I therapeutic dosage.   
 
The IAA activity received by a Graves’ disease patient should therefore fall 
within the recommended range of 110 MBq to 350 MBq. A 5% value 
difference between the 6-hr and 24-hr RAIU values would make a less than 1 
MBq difference to the CAA for the Graves’ disease patient as long as the 
aimed IAA stays the same. At the UNMD a 5% value difference between the 
6-hr and 24-hr RAIU values would be acceptable, as the patient radiation 
dosage received would not be significantly higher. Hence, if it could be 
proven that there is in most of the Graves’ disease patients a 5% or less 
value difference between the 6-hr and 24-hr RAIU values, only the 6-hr RAIU 
can be used to determine the CAA. 
 
 
1.2 STATEMENT OF THE PROBLEM 
 
The 24-hr 131I RAIU measurement following the 6-hr 131I RAIU measurement 
for patients with Graves’ disease requires a costly prolonged stay in hospital 
or the return to the clinic on an outpatient basis. McDougall (1991:86) 
indicates that there is a possibility for same day diagnosis, dosage calculation 
and treatment of the patient, as there are some reports of a predictable 
correlation between the early (6-hr) RAIU and the late (24-hr) RAIU values. If 
the 6-hr 131I RAIU value alone confirms to be sufficient to calculate the 
therapeutic administration activity for Graves’ disease patient cost and 
hospital stay could be significantly reduced. 
 
1.2.1 Investigation questions 
To address the problem statement, the investigation sought to answer the 
following questions: 
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 Is the 6-hr 131I RAIU value alone sufficient to calculate the optimal 
therapeutic administration activity for 131I for patients with Graves’ 
disease? 
 How do the 6-hr and 24-hr 131I RAIU values correlate with the T4 
values of patients with Graves’ disease?  
 How do the 6-hr 131I RAIU values correlate with the 24-hr RAIU values 
when the transit patterns in patients with Graves’ disease are 
analysed? 
 
 
1.3 GOAL, AIM AND OBJECTIVES OF THE INVESTIGATION 
 
In the next section a closer look will be taken at the goal, aim and the 
objectives of the investigation. 
 
1.3.1 Aim 
The overall aim of the investigation is to analyse the 6-hr and 24-hr 131I RAIU 
values of patients with Graves’ disease at Universitas Hospital. As to 
determine if there is a correlation between the 6-hr and 24-hr RAIU values to 
establish if only the 6-hr RAIU value can be used to calculate the therapeutic 
dosage for Graves’ disease. 
 
1.3.2 Objectives 
To achieve the aim, the following steps were taken: 
 To serve as a background to the investigation, a literature survey 
relating to the RAIU values of patients with Graves’ disease was 
undertaken. 
 A retrospective analysis was performed by comparing the 6-hr and 24-
hr 131I RAIU values of patients with proven Graves’ disease at the 
UNMD. 
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 To answer the investigation questions, the data obtained from the 
literature and the retrospective analysis was then analysed, 
summarised and compared. 
 
 
1.4 SIGNIFICANCE OF THE INVESTIGATION 
 
A 6-hr 131I RAIU value which does not differ significantly from the 24-hr value 
may lead to a decrease in hospitalisation time, as the patient will not have to 
stay overnight or return the next day for the 24-hr 131I uptake value (Hayes et 
al. 1990:519). If the 6-hr 131I uptake value does not correlate with the 24-hr 
value, the latter will be essential to calculate the correct 131I therapeutic 
administration activity. The disparity between the 6-hr and 24-hr 131I uptake 
values may justify the extra cost with regard to prolonged hospitalisation or 
additional outpatient visits. 
 
 
1.5 SCOPE OF THE INVESTIGATION 
 
The investigation was conducted in the field of nuclear medicine health care. 
This field provides a diagnosis of functional thyroid disease through the 131I 
uptake measurement. The topic that was addressed was the comparison 
between the 6-hr and 24-hr 131I RAIU values of patients with Graves’ disease 
at the UNMD. 
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1.6 METHODS OF INVESTIGATION 
 
 
1.6.1 Investigation design 
The investigation design was two-fold. Firstly, a literature review was carried 
out to determine the significance of the 6-hr and 24-hr RAIU values in patients 
with Graves’ disease. Secondly, a retrospective analytical investigation was 
conducted to analyse and compare the 6-hr and 24-hr RAIU values of 
patients with proven Graves’ disease in the Free State referred to the UNMD 
(see Figure 1.2 for the investigation design). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Investigation design 
 
 
 
1. Retrieval of patient data 
2. Investigation group 
inclusion/exclusion  
(Appendix C:5) 
3. Formulation of data base (for 
example Excel) 
4. Analysis of the 6-hr and 24-hr 
RAIU values (n=124) 
 
5. Comparison and 
interpretation of data 
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1.6.2 Patient inclusion and exclusion criteria 
The investigation included patients with confirmed Graves’ disease who had 
undergone both 6- and 24-hr 131I RAIU studies at the Universitas Hospital 
from the beginning of 2004 to the end of 2005. Graves’ disease was 
confirmed by the following factors at the UNMD namely: Suppressed TSH; 
elevated T4 or T3; a diffuse increased uptake of 99mTc-pertechnetate; and an 
increased 6-hr and 24-hr 131I RAIU value. The UNMD statistics showed that 
178 patients were diagnosed with Graves’ disease during this period. 
 
Male and female patients, varying in age, were included. Patients with serious 
systemic disease, iodine contamination, thyroid nodules or other causes of 
hyperthyroidism were excluded from the study. These factors were excluded 
due to their effect on the physiology of the thyroid and therefore the uptake of 
RAI (see paragraph 1.1.6). 
 
 
1.7 FORMULATION OF DATABASE 
  
The data obtained from the patient files was noted on the different data 
sheets (see Appendix A) for further analysis. There was a need for a data 
sheet containing information about patient 131I RAIU values and biochemistry 
information (see Appendix A:1). The second data sheet contained information 
about the patient age and sex (see Appendix A:2). A data sheet to note the 
patient 6- and 24-hour therapeutic dosage information (see Appendix A:3) 
was used. 
  
 
 
 
 
 16 
1.8 DATA ANALYSIS 
 
The department of Biostatistics at the University of the Free State (UFS) was 
consulted for recommendations regarding the management of data and the 
processing of results (see Appendix D:7). Chapter 3 outlines the method used 
for the data analysis of this research project.  
 
 
1.9 ETHICAL ASPECTS 
 
The protocol was approved by the Ethics Committee of the UFS (ETOVS Nr. 
40/06) with all the necessary application forms to evaluate the ethical aspects 
(see Appendix F:8). There was no need to obtain consent from the Radiation 
Control Committee (RCC), as the 131I uptake measurement done at the 
Universitas Hospital falls within the RCC rules and regulations. Letters 
requesting permission (see Appendix F:9) to perform this research project at 
the UNMD were written to the chief specialist and the director of the UNMD. 
Informed consent was obtained from the director of the Universitas Hospital 
(see Appendix F:10) and the chief specialist (see Appendix F:11) for patient 
data to be used for this retrospective investigation. 
 
 
1.10 ARRANGEMENT OF THE INVESTIGATION 
 
The course of the investigation report, the methods used to find answers to 
the investigation questions, and the outcome of the study will be reported on 
as follows: 
 
 17 
In this chapter, Chapter 1, a brief introduction and background to the 
investigation was given.  
 
Chapter 2, The 131I thyroid uptake procedure: Background and related 
factors, as well as the uptake technique, the calculation of the 131I RAIU and 
the calculation of the 131I therapeutic dosage will be discussed and explained 
in detail. 
 
Chapter 3, Investigation design and methods, will provide a description of 
the methodology applied in the investigation. Theoretical aspects of the study 
design and the methods of investigation will be discussed. Measurement and 
analysis factors of the retrospective investigation will be reported in this 
chapter. 
 
Chapter 4, Results and findings, will be presented in the form of appropriate 
tables and figures. 
 
Chapter 5, Discussion and recommendations, the final chapter in the 
research report, will in particular deal with the outcome of the study. 
Recommendations regarding the diagnosis and RAI treatment of patients with 
Graves’ disease at the UNMD and possibilities for future research will be 
provided. 
 
 
1.11 CONCLUSION 
 
In the SAHS it is each health worker’s responsibility to find ways to reduce 
health care cost and improve health service to the public. The investigation 
determined if the 6-hr 131I RAIU value alone can be used to calculate the 
therapeutic dosage for Graves’ disease and if hospital and patient expenses 
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can be reduced significantly. Therefore, to explore the possibility of using a 6-
hr 131I RAIU value alone, analysing and comparing the 6-hr and 24-hr 131I 
RAIU values seemed meaningful. 
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CHAPTER 2 
 
 
THE 131I THYROID UPTAKE PROCEDURES: BACKGROUND 
AND RELATED FACTORS 
 
 
2.1  INTRODUCTION 
 
During the 1940s the RAIU test was introduced and is now used worldwide in 
the evaluation of thyroid function (Hayes et al. 1990:519). Since the thyroid 
gland has the ability to accumulate iodine, RAI is used as the basis for the 
RAIU test (Grayson 1960:397). The thyroid gland is the ideal organ for the 
use of 131I for the RAIU test, as it is the only tissue to retain iodine for a 
prolonged interval (Volpé 1977:2). The RAIU test may give the perception of 
being simple, but the dynamics of normal iodine metabolism is complicated 
and there are various factors that can influence the diagnostic results 
(Grayson 1960:397). Quantitatively the avidity of the thyroid gland for iodide 
is established by the RAIU test or qualitatively by using a thyroid scan (Meier, 
Brill, Becker, Clarke, Silberstein, Royal & Balon 2002:857). 
 
A variety of diagnostic procedures that provide information about the thyroid 
function exists. Some examples are thyroid iodine clearance, the thyroid 
iodine accumulation rate, the thyroid accumulation gradient, the 131I 
conversion ratio, the 131I urinary excretion and a number of thyroid scanning 
procedures (Grayson 1960:397). Some of the above-mentioned procedures 
have specific value in the study of thyroid function (Kasper et al. 2005:2115), 
but the 24-hr RAIU test has been the standard test in most centres worldwide. 
The RAIU test is also preferred as the diagnostic test of choice at the UNMD 
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to provide information about the thyroid function and iodine status. A variety 
of time intervals from one to 48 hours has been used for the measurement of 
uptake in the thyroid for the RAIU test (Grayson 1960:397; Wagner et al. 
1995:598). The time intervals used at the UNMD for the RAIU test with 
Graves’ disease patients are six hours and 24 hours after 131I administration.  
 
The radionuclide needed for the RAIU must have characteristics such as 131I 
to be taken up and organified in the thyroid gland (Wagner et al. 1995:598). 
131I is a radionuclide which has been used over the years to diagnose thyroid 
disease in different ways, including the RAIU test (Grayson 1960:397). At the 
UNMD 131I is the radionuclide of choice for the RAIU test. 
  
In 1835 Robert Graves’ described the clinical signs of three women, namely 
goitre, palpitations, forceful heartbeat and tachycardia and from this the 
eponym Graves’ disease was derived (McDougall 1991:79). The signs that 
are usually present with Graves’ disease are hyperthyroidism, diffusely 
enlarged thyroid gland and in some patients ophthalmopathy, dermopathy, 
finger clubbing and nail changes (Kasper et al. 2005:2114). McDougall 
(1991:92) stated that Graves’ disease is an autoimmune disorder related to a 
specific organ, namely the thyroid gland. Graves’ disease causes high levels 
of thyroid hormones in the blood (McDougall 1991:79) and is the most 
common cause of hyperthyroidism (Lind 2002:453). In order to confirm 
Graves’ disease and differentiate it from other causes of hyperthyroidism, a 
complete clinical evaluation, biochemical measurements, RAIU and - if 
indicated - scintigraphy must take place (McDougall 1991:79). 
 
Various scientists have contributed to the discovery of the use of iodine in 
making a diagnosis and the treatment of Graves’ disease. A short historical 
review of these scientists’ discoveries will be provided to give an overview of 
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the use of iodine in Nuclear Medicine Departments (NMD) as we currently 
know it. 
 
 
2.2  HISTORICAL REVIEW OF THE USE OF RAI 
 
Various scientists and clinicians, namely Baumann, Marine, Plummer, Fermi, 
Compton, Chapman and Evans as cited in Chapman and Maloof (1955:263-
267) made the following contributions to the diagnosis and treatment of 
thyroid disease: During the 1890s Baumann discovered iodine in the thyroid 
gland and recognised the avidity that the thyroid holds for iodine (Chapman & 
Maloof 1955:263). Marine made another important contribution by 
demonstrating the value of iodine in the prevention of iodine-deficient 
endemic goitres. In 1923 Plummer disclosed a report in which he indicated 
the use of iodine in the smoothing of the post-operative course of patients 
with hyperthyroidism (Chapman 1983:2043). Because of this concept of 
Plummer’s report, various thyroid clinics then proceeded to give iodine before 
and after surgery in the place of thyroidectomy. At the Massachusetts 
General Hospital, Means and his associates described the iodine response, 
the effective dosage, the cause of failure, as well as the several clinical 
results of iodine treatment (Chapman 1983:2043). 
 
Chapman and Maloof (1955:264) further report that Fermi, an Italian scientist, 
succeeded in producing radioactive iodine. Compton (as quoted in Chapman 
& Maloof 1955:264) based the use of RAI in treating patients with 
hyperthyroidism on the following three concepts: 
  The thyroid has a natural avidity for collecting either stable or 
radioactive iodine. 
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  RAI decays in the thyroid by emitting high-energy beta rays, which only 
penetrate a few millimetres of thyroid tissue.  
  Beta-rays can destroy thyroid tissue in a similar fashion as the 
secondary electrons produced by x-rays. 
 
 
In 1946 Chapman and Evans concluded that RAI on its own is effective in 
controlling hyperthyroidism (Chapman & Maloof 1955:264). In 1951 the IAEA 
reported that more than 130 hospitals and clinics were using 131I in the 
treatment of hyperthyroidism. RAI has become an accepted form of therapy 
due to the research that has been performed in past years (Chapman & 
Maloof 1955:266). The UNMD also uses 131I mainly as therapy choice for the 
treatment of Graves’ disease. 
 
 
2.3  GRAVES’ DISEASE 
 
A background and an understanding of the pathogenesis, etiology, 
morphology, clinical correlation and prevalence of Graves’ disease are 
needed to understand the role of the 131I RAIU test in the diagnosis and 
treatment of Graves’ disease. 
 
2.3.1 Pathogenesis  
The pathogenesis of Graves’ disease was suggested by Robbins and Kumar 
(1987:681) to be an autoimmune disease. The characteristics that indicate 
Graves’ to be an autoimmune disease are the presence of thyroid 
microsomal autoantibodies in 85% of patients with Graves’ disease and 
thyroglobulin antibodies in about 30% of these patients. The pathologic 
characteristics of Graves’ disease are a diffusely enlarged, soft and vascular 
thyroid gland (Braunwald et al. 1987:1743). Another essential pathological 
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characteristic present in Graves’ disease is the presence of parenchymatous 
hypertrophy and hyperplasia. 
 
2.3.2 Aetiology 
The specific cause of Graves’ disease is not yet fully known (Braunwald et al. 
1987:1743). There is a variation of manifestations and no single factor is 
responsible for this condition. Hyperthyroidism, the main disorder in Graves’ 
disease, is caused by a haemostatic disruption resulting from the presence of 
an abnormal thyroid stimulator. 
 
2.3.3  Morphology  
The thyroid gland of a patient with Graves’ disease is in most cases diffusely 
and symmetrically enlarged (Robbins & Kumar 1987:681). When dissected, 
the thyroid gland in a patient with Graves’ disease has a red-brown muscle 
like appearance. In the untreated Graves’ disease patient the most important 
histological features have a “too many follicular cells and too little colloid” 
appearance. 
 
2.3.4 Clinical correlation 
A patient with Graves’ disease may present with a diffuse goitre, pretibial 
myxoedema and ophthalmopathy, but over 50% of these patients do not 
present with all these signs (Freitas 1999:297). Therefore Graves’ disease 
should be confirmed biochemically by suppressed serum TSH (<0.05 mIU/L) 
and elevated free T4 or T3 levels (Freitas 1999:297-298). Graves’ disease is 
best distinguished from other thyrotoxic entities by a thorough clinical history 
and examination, which is then combined with a 99mTc-pertechnetate thyroid 
scan (to confirm a diffuse enlarged gland with homogeneous increased 
uptake) and an increased 24-hr 131I RAIU value (Freitas 1999:298). 
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2.3.5 Prevalence 
Graves’ disease is especially common in the thirty- to forty-year age group 
but can occur at any age (Braunwald et al. 1987:1743). It manifests more in 
women than in men. For investigation purposes it is always interesting and of 
value to look at the prevalence of the disease; to determine if it stays 
constant as time goes by; and whether the prevalence is the same for 
different parts of the world. For future investigation purposes it would be 
interesting to compare UNMD prevalence investigation data with data stated 
by Braunwald et al. (1987:1743). 
 
  
2.4 THYROID HORMONES 
 
The thyroid hormones influence the uptake of iodine by the thyroid gland and  
therefore the RAIU value. For better understanding of the physiologic 
interaction between the thyroid hormones and iodine uptake a short summary 
of applicable physiological factors is given. 
 
2.4.1 Formation and secretion of thyroid hormones 
The hormones mainly secreted by the thyroid gland are T3 and T4 (Ganong 
1995:291; Kasper et al. 2005:2105-2106). These hormones are from the 
iodine-containing amino acids monoiodotyrosine (MIT) and diiodotyrosine 
(DIT). Thus T3 and T4 are synthesised by iodination and condensation of 
thyrosine molecules in the colloid that binds in peptide linkage with 
thyroglobulin. Through the process of deionisation of T4 in the peripheral 
tissues T3 is formed. Other compounds like MIT and RT3 are also present in 
the thyroid venous blood. RT3 is inactive, whereas the hormones T3 and T4 
are active. T3 is more active than T4. The thyroid cells therefore have three 
vital functions, namely: Firstly, to transport and collect iodine; secondly, to 
synthesise thyroglobulin and store it in the colloid; and, lastly, to remove the 
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thyroid hormones from thyroglobulin and secrete the thyroid hormones into 
the circulation. 
 
2.4.2 The metabolic pathways of iodine and the thyroid hormones  
The gastrointestinal tract (GIT) provides a medium through which iodide, 
iodine and iodate taken by mouth are rapidly absorbed and then transferred 
into the bloodstream (Chapman & Maloof 1955:266). Iodine and iodate are 
reduced to iodide before being absorbed. Through the process of diffusion 
iodide is transferred from the bloodstream into the iodide space of the body. A 
fraction of iodide is concentrated by the thyroid gland to form thyroid 
hormones while the kidneys excrete the rest. The two thyroid hormones T4 
and T3 are bound in the bile as glucuronides. There is an excretion of iodine 
in the faeces of humans of about 5-12%. 
 
The thyroid iodine metabolism can be categorised in the following three 
processes (Grayson 1960:397-398): 
   Iodide trapping: In this process iodide is selectively concentrated within 
the thyroid cell to provide the substrate for subsequent steps.  
  Hormonal synthesis: This process includes the activation of iodide by 
oxidation, with sequential iodination of tyrosine residues of 
thyroglobulin to form monoiodotyrosines and diiodotyrosines. The 
binding of iodotyrosines gives rise to T4, T3 and traces of other iodo-
thyronines. 
   Hormonal release: Through thyroglobulin the amino acids are liberated 
by proteolytic enzyme(s) secreted by the thyroid cell. Inside the thyroid 
follicular cell the iodotyrosines are selectively deiodinated, but this 
does not include T4 and T3 that are spared and permitted to enter the 
bloodstream. 
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2.4.3  Thyroid hormone measurement 
Various diagnostic tests are available to distinguish between single toxic 
nodule, toxic multinodular goitre and induced iodine hyperthyroidism 
(McDougall 1991:81). These tests, as previously mentioned, include clinical 
evaluation, biochemical measurements, RAIU and scintigraphy of the thyroid. 
Laboratory methods (in vitro tests) of the thyroid hormones give an indication 
of thyroid function (Early & Sodee 1995:623). Increased levels of thyroid 
hormones are present in Graves’ disease because of the increased synthesis 
and secretion of thyroid hormones (Harbert & Da Rocha 1984:30). Therefore, 
Graves’ disease can be confirmed by biochemical tests that included the in 
vitro measurement of thyroid hormones (T4 and T3) and TSH (McDougall 
1991:92). 
 
The normal biochemical value for T4 is between 4.7-11 µg/dl and for TSH 
after 400 to 500 µg of TRH is 5-25 µU TSH/ml (Kaplan 1985:871; Kasper et 
al. 2005:2108). Graves’ disease patients’ laboratory test indicate an 
increased serum T4 or serum T3 reduced TSH and increased RAIU 
(Braunwald et al. 1987:1744). Therefore, in Graves’ disease, there is an 
abnormally increased T4 and 131I RAIU values and both of these diagnostic 
tests provide information about thyroid function. As T4 and RAIU tests confirm 
the diagnosis for Graves’ disease, it would be valuable to see if there is any 
correlation between the values of the thyroid hormones and RAIU (see 
Appendix A:1). 
 
Harbert and Da Rocha (1984:35) mention that a good indicator of thyroid 
hormone production will always be TSH. Other laboratory tests of thyroid 
hormones such as TSH also give an indication of thyroid function (Early & 
Sodee 1995:623). The value of TSH concentrations in Graves’ disease is 
typically below 0.05 µU/ml (Early & Sodee 1995:625). It would be interesting 
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to see if there is any correlation between values of TSH and 131I RAIU, as 
both provide information about thyroid function in Graves’ disease. 
 
 
2.5  NORMAL DAILY INTAKE OF IODINE 
 
Iodine intake can consequently influence the uptake 131I by the thyroid gland 
for the RAIU test. The recommended daily intake of iodine for adults to satisfy 
the physiologic requirement is two to four µg per kilogram (kg) of body weight 
(Grayson 1960:399). The average daily urinary iodine excretion is about 150 
µg and the mean of the daily normal thyroid accumulation of iodine is about 
75 µg. The optimal daily iodine intake, without affecting the uptake of the 
thyroid gland, is 200 µg for an adult weighing 70 kg. The amount of iodine to 
depress RAIU in the case of Graves’ disease is one milligram (mg) of iodide 
(Grayson 1960:400). 
 
 
2.6  SOURCES OF EXCESS IODINE INTAKE 
 
There are various external sources of iodine, for example drugs, iodised salt, 
foods and X-ray contrast media (Grayson 1960:400). The iodine metabolism 
can be affected by various drugs and toxic substances that contain iodine 
(Grayson 1960:397). These drugs and toxic substances act as discrete sites 
in the steps involved in the formation and release of thyroid hormones in the 
thyroid metabolism process. As these drugs and toxic substances influence 
the thyroid metabolism, they will also affect the RAIU test. As various 
substances and conditions influence the 131I RAIU, a short summary of these 
factors is provided as part of the exclusion criteria for the investigation report 
(Grayson 1960:397). 
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2.6.1 Medication 
Potassium iodide and other iodides are present in various medication used. 
Lugol’s solution, for example, contains five to eight mg of iodine per drop. 
Lower RAIU values will be the result of the administration of these 
preparations. 
 
2.6.2 Vitamins and minerals 
Grayson (1960:401) suggests that even some vitamin tablets containing 
iodide are sufficient to lower the 24-hr 131I RAIU values significantly. 
 
2.6.3 Iodine in food   
The 131I RAIU values can be lowered by increased dietary iodine provided by 
an excessive seafood diet (Grayson 1960:402). Other foods that are not from 
the sea may have a variation in their iodine content. This factor of iodine 
content is mainly dependent on the iodine concentration of the soil in which 
they were produced. 
 
2.6.4 Iodine in X-ray contrast media 
During X-ray procedures various types of contrast media (for example 
Urograffin) are used which contain large amounts of iodine (Grayson 
1960:402). X-ray contrast media can lower the 131I RAIU values, because in 
some of these contrast media, iodine is released from its organic binding as 
iodide and increases the total body pool. The excess iodide that is produced 
decreases the values of the 131I RAIU test. The RAIU test may be interfered 
with as long as one month from iodinated compounds used during 
intravenous pyelography (Grayson 1960:403). 
 
2.6.5  Hormones   
Hormones can have an effect on the uptake of iodine by the thyroid gland 
and various have been studied in this regard, including adrenocorticotropic 
 29 
hormone (ACTH), cortisone, epinephrine, desiccated thyroid, T4, T3, 
oestrogen, progesterone, desoxycorticosterone, testosterone and the TSH. A 
decrease in value of the 131I RAIU can be caused for example by cortisone 
(Grayson 1960:407). The 24-hr 131I RAIU value is increased by epinephrine. 
 
131I RAIU uptake value is decreased by the administration of desiccated 
thyroid, T4 and T3, because this causes the inhibition of the release of TSH by 
the anterior pituitary (Grayson 1960:408). The hormones progesterone and 
testosterone also decreased 131I RAIU test values, whereas estrogens 
showed no consistent changes.    
 
2.6.6 Antibiotics 
Antibiotics affect the 131I uptake by the thyroid gland (Grayson 1960:409). 
Therefore, antibiotics can influence the values of the 131I RAIU test. As 
antibiotics can influence the values of the 131I RAIU test, patients in the 
investigation group that used antibiotics were excluded from the investigation. 
 
 
2.7  INDICES OF THYROID FUNCTION 
 
Various accurate indices of thyroid function have contributed to the process 
of thyroid diagnostic testing, for example value measurements of TSH, T4, T3 
and the detecting of thyroid stimulating immunoglobulins (TSI) (Hayes et al. 
1990:519). According to Chapman and Maloof (1955:267), the thyroid 
function may be determined by several procedures, namely: 
    RAIU test and the retention of RAI by the thyroid. 
   The protein-bound iodine of the serum procedure in which the 
concentration of thyroid hormone is estimated in blood. 
    The basal metabolic rate. 
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The 131I RAIU test is the thyroid function procedure that will mainly be 
concentrated on to perform the investigation. 
 
 
2.8  UPTAKE OF RAI IN THE THYROID GLAND 
 
The uptake value obtained by the RAIU test is determined by the function of a 
thyroid gland. Consequently, the RAI value could be influenced by whether 
the thyroid gland is in a euthyroid, hypothyroid or hyperthyroid functional 
state. The 5th MIRD Dosage Estimate Report (1975:858) states that the 
maximum uptake of RAI in a euthyroid patient is approximately two days after 
administration. The maximum uptake of iodine in a Graves’ patient and a 
euthyroid subject will be different as the RAIU of a Graves’ patient is 
increased. The time of maximum uptake of iodine in the thyroid is also 
dependent on the physical half-life of the radionuclide of iodine administered. 
The oral administration of RAI will delay the appearance of RAI in the blood 
by 10 to 15 minutes compared to an intravenous injection, but has minimal 
effect on the actual levels of activity in the blood and no relative effect on the 
final thyroid uptake (MIRD Dosage Estimate Report 1975:858). Therefore, 
whether the RAI is orally or intravenously administered, will not affect the 
value obtained from the RAIU test. At the UNMD the 131I for the RAIU test is 
orally administered. 
 
 
2.9  131I CHARACTERISTICS FOR UPTAKE, MEASUREMENT 
AND TREATMENT  
 
131I has characteristics that make it suitable for the uptake and measurement 
of RAI in the thyroid gland. 131I has the radionuclide nature to be organified 
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and taken up by the thyroid gland and this characteristic makes it ideal for 
RAIU test use. The radionuclide 131I is also a beta particle emitter with a 
physical half-life of 8.1 days, a gamma ray of 364 kilo electronvolt (keV) and a 
beta particle with a maximum energy of  610 keV (Meier et al. 2002:856). 131I 
has an electron energy of 192 keV and its range in tissue is 0.8 millimeter 
(mm). 131I in the thyroid gland usually has an effective half-life of 5.4-6.4 days 
(Early & Sodee 1995:629). 
 
Wagner et al. (1995:598) indicate that the 24-hr 131I uptake measurement 
value is highly recommended for the treatment of Graves’ disease and toxic 
nodular goitre. 131I is used predominantly for thyroid uptake measurement 
even though it has a high radiation dosage. The administration activity 
suggested by the IAEA (1961:535) for 131I uptake measurement is to be not 
more than 0.37 MBq 131I. The radiation exposure for 131I to the thyroid is very 
high, namely 0.27-0.54 Gy/MBq. At the UNMD the single dosage used to 
calculate the 6-hr and 24-hr 131I RAIU values is between 0.30 and 0.37 MBq 
and still falls within the IAEA recommendations. 
 
In order to prevent volatilisation of iodine, sodium iodide is supplied in a basic 
solution containing a reducing agent to minimise the conversion to iodate 
(MIRD Dosage Estimate Report 1975:857). Sodium iodide is available in 
liquid and capsule forms for administration. Sterile solutions of sodium iodide 
are also available for intravenous use, even though iodide is mostly 
administered orally. Very small quantities of stable iodine might be present in 
131I, but it does not affect the biological distribution, therefore the radionuclide 
and radiochemical purity can be assumed to be 100%. 
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2.10  CLINICAL RESPONSE TO 131I 
 
Chapman and Maloof (1955:282) state that RAI has a good response as 
treatment option for Graves’ disease, for example the relief of symptoms, an 
increase in weight, a decrease in the size of the goitre and a fall in the indices 
of thyroid function. The reason why the UNMD uses 131I to treat Graves’ 
disease patients is because of favourable experience in this regard. 
 
 
2.11 131I THERAPY DOSAGE CALCULATION 
 
Consensus has not been reached worldwide about treating Graves’ disease 
patients with a fixed dosage or a calculated 131I dosage (therapeutic 
administration activity) (Lind 2002:454). There is a variety of procedures and 
approaches that are followed in the management and treatment of Graves’ 
disease (Hayes et al. 1990:520). It is for this reason that the method of 
therapy dosage calculation in Graves’ disease patients for different 
instituitions may vary.  
 
Various formulas are used to calculate the treatment dosage for Graves’ 
disease patients (Nordyke & Gilbert 1991:414). Formulas that use Ci/g of 
thyroid tissue to calculate the treatment dosage are not very accurate, since it 
is so difficult to estimate thyroid weight by palpation. The formula that uses 
thyroid weight to calculate the treatment dosage is not used at the UNMD. 
Thyroid weight estimation by palpation is even difficult when done 
consistently by one person or aided by scinitigraphy. Compared to the thyroid 
weight estimation treatment formula, the fixed dosage approach is a simpler 
alternative for deciding on the amount of 131I to be administered. 
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2.12 CALCULATION OF THE RAIU VALUE 
 
The definition provided by Becker et al. (2003:33) for the thyroid uptake test 
is the measurement of the fraction of an administered amount of RAI that 
accumulates in the thyroid at selected times following ingestion. The 
clearance of iodine by the thyroid is corresponding to the RAIU value 
(Hamburger 1971:287). According to Becker et al. (2003:33), the 131I thyroid 
uptake test has some common indications, namely: 
     It aids in calculating the amount of 131I to be administered for the 
therapy of hyperthyroidism due to Graves’ disease or toxic nodular 
goitre. The ideal is to perform the 131I RAIU test close to the time of 
treatment. 
    It provides information to distinguish subacute or painless thyroiditis 
and factitious hyperthyroidism from Graves’ disease and other forms of 
hyperthyroidism. 
   It also aids the diagnosis of hyperthyroidism and confirming the 
diagnosis, yet 131I thyroid uptake measurement is of little value in the 
diagnosis of hypothyroidism. 
 
A correctly designed protocol can eliminate technical errors. This is another 
reason why the RAIU test is preferred (Hamburger 1971:287). The RAIU 
value can provide unique information about thyroid function that can play an 
important role in the management of the patient. The information obtained by 
the RAIU value must be interpreted with due regard to the clinical picture in 
order to obtain an optimal diagnosis. The RAIU test can be used to 
distinguish between a patient with thyroiditis and those with Graves’ disease 
(Hayes et al. 1990:519). The RAIU value for thyroiditis is very low, as for 
Graves’ disease the RAIU value can be high to very high. The uptake of RAI 
in the thyroid is increased in the case of Graves’ disease, toxic multinodular 
goitre or toxic adenoma (Kaplan 1985:878). 
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The 24-hr RAIU value has become very popular over the past 60 years with 
regard to thyroid function testing (Hamburger 1971:287). Hayes et al. 
(1990:519) state that the 24-hr RAIU value may only be used for the sake of 
tradition, as it demands a costly prolongation stay in hospital or the return of 
outpatient visits to the clinic. Hamburger (1971:287) points out that it is only 
necessary to obtain a single RAIU value and that any value between 15 and 
30 hours after administration will be sufficient. According to Hamburger 
(1971:287), the need for short-interval RAIU values has also been 
overstressed. Hayes et al. (1990:519) had a theory that the early RAIU value 
could be used to calculate the 131I therapeutic dosage (administration activity) 
for Graves’ disease. The results obtained by the three- to six-hour RAIU 
value were supposed to be comparable to those of the 21- to 28-hour RAIU 
value for the calculation of the 131I therapeutic dosage in the case of Graves’ 
disease patients. McDougall (1991:86) indicates that there is a possibility for 
same day diagnosis, dosage calculation and treatment of the patient, as there 
are some reports of a predictable correlation between the early (6-hr) RAIU 
and the late (24-hr) RAIU values. 
 
 
2.13 131I THYROID UPTAKE TECHNIQUE 
 
The 131I RAIU technique described by the IAEA is used worldwide as the 
basis for thyroid uptake techniques. The UNMD uses the 131I RAIU technique 
described by the IAEA. The 131I thyroid uptake technique described by the 
IAEA is outlined in Chapter 1. 
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2.14  NORMAL VALUES FOR THE 131I RAIU TEST 
 
In Columbia, Missouri, the normal values for the 24-hr RAIU test are 
considered to be as follows: Low 0-15%, normal 15-45% and high 45-100% 
(Grayson 1960:397). The normal values for 131I RAIU test vary at different 
clinics, due to the variation in methods of instrumentation, time intervals and 
differences in mean iodine intake (Chapman & Maloof 1955:267). The 
determination of an exact standard statistical expression of normal values is 
not possible, due to the difference in measuring techniques, the difference of 
frequency distribution and a range of “normal” uptake in geographic areas. 
Therefore each nuclear medicine department should thus determine its own 
normal RAIU values. The normal RAIU values determined for the UNMD are 
between 15-35%.  
 
 
2.15 INTERPRETATION CRITERIA 
 
In order to make an interpretation of RAIU values obtained from a patient, 
reference values for thyroid uptake determinations of euthyroid individuals 
are needed (Becker et al. 2003:35). Each specific medical facility must 
determine its own RAIU reference values, as it is influenced by geographical 
changes. If the literature is consulted for the normal range of values for 
thyroid uptake measurement, it usually ranges between 6-18% for 4-hr RAIU 
and 10-35% for the 24-hr RAIU. Each facility must obtain its own specific 
normal thyroid uptake values according to its equipment, standard, uptake 
phantom and the individuals from its population with their iodine intakes. 
 
In order to make a diagnosis of the patient the interpretation of the results 
requires some knowledge of the patient’s history, laboratory data, as well as 
the physical examination (Becker et al. 2003:35). As mentioned in paragraph 
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2.6, iodine containing materials, thyroid hormone or antithyroid drugs also 
have an influence on the RAIU. It is therefore of particular importance to 
check the patient’s medical history. The information about the ingestion of the 
last iodine-containing medication is also of significance in the evaluation of 
the thyroid uptake results (Becker et al. 2003:35-36). 
 
 
2.16 GRAVES’ DISEASE TREATMENT OPTIONS 
 
Different treatment options for Graves’ disease are used in different parts of 
the world (Lind 2002:453). Even though over the years knowledge of the 
actiology and pathogenesis of Graves’ disease has increased, there is still no 
straightforward therapeutic option (Peters, Fischer, Bogner, Reiners & 
Schleusener 1995:186). The overall goal of the different treatment options is 
the same, namely to eliminate the hyperthyroid state present in Graves’ 
disease (Lind 2002:453). The therapeutic treatment choice by the physician 
for treating Graves’ disease depends on cost, convenience, dietary and 
medical exposure to iodine; data concerning disadvantages and advantages 
of each treatment option; availability of surgical expertise; and personal bias 
(Solomon, Glinoer, Lagasse & Wartofsky 1990:1518). There are various 
factors that contribute to the choice of treatment, for example the 
geographical location, the size of the goitre, the age of the patient, the 
personal experience of the treating physician, and the degree of Graves’ 
disease (Lind 2002:453). There are also other factors that play a role in the 
treatment of Graves’ disease, for example patient economic aspects; cost 
associated with long-term antithyroid drugs; the need for ablative therapy; the 
possibility of recurrence; and the use of RAI treatment as first-line therapy 
(Lind 2002:453). There are mainly three treatment options for patients with 
Graves’ disease, namely antithyroid drugs, thyroidectomy and RAI treatment 
(Hennemann, Krenning & Sankaranarayanan 1986:1369).  
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2.16.1 Antithyroid drugs 
Antithyroid drugs are an alternative treatment option if radioiodine treatment 
is not favoured (Hennemann et al. 1986:1371). Antithyroid drugs may not be 
so effective in treating patients with Graves’ disease and toxic multinodular 
goitre (Hennemann et al. 1986:1370). There is a relapse as high as 50% in 
patients with Graves’ disease if they discontinue their antithyroid drug 
treatment (Peters et al. 1995:186). However, there is also an incidence of 5% 
of antithyroid drugs in causing allergic and toxic reactions in adult patients 
(Hennemann et al. 1986:1369). This low level of effectiveness of antithyroid 
drugs is a major disadvantage. Antithyroid drugs interfere with the 
organification process of iodine in the thyroid gland and this is the reason why 
the patient should stop all antithyroid medication before going for a 131I RAIU 
test (McDougall 1991:87). The main role of beta blockers is to serve as an 
adjuvant while the patient is receiving antithyroid drugs or 131I to relieve the 
symptoms of hyperthyroidism (McDougall 1991:89). 
  
2.16.2 Thyroidectomy 
There is a high incidence of operative complications related to thyroidectomy, 
therefore it would not be a good substitute of RAI (Hennemann et al. 
1986:1371). Holm, Lundell, Israelsson and Dahlqvist (1982:106) also point 
out that the incidence of hypothyroidism after 131I treatment is higher than 
after surgery. Graves’ disease patients who underwent a thyroidectomy have 
a relapse rate of 1-12% (Hennemann et al. 1986:1370). The main 
disadvantages of thyroidectomy are the incidence of hypothyroidism 
afterwards and the risks associated with the operation (Hennemann et al. 
1986:1370). There is an chance of 35-49% for developing hypothyroidism 
after thyroidectomy (Hennemann et al. 1986:1370). Thyroidectomy has the 
risk of damaging the recurrent laryngeal nerve and other surgical 
complications (Peters et al. 1995:186). Thyroidectomy is considered as a 
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treatment option at the UNMD in Graves’ disease patients with very large 
goitres. 
 
2.16.3 RAI treatment 
131I therapy in the case of Graves’ disease has a very good safety record 
(Holm et al. 1982:106). In comparison with other therapeutic alternatives 131I 
therapy is safe and there is also no increased risk of developing thyroid 
cancer (Holm et al. 1982:100). The disadvantages of RAI treatment with 131I 
can be the potential hazard of developing hypothyroidism and genetic 
abnormalities (Hennemann et al. 1986:1370). The study results that are 
available show that the administration of RAI had no significant impact on the 
incidence of leukaemia. There is evidence that benign and malignant thyroid 
tumours can be caused by radiation. The radiation dosages received by the 
thyroid in the above-mentioned cases are much lower [from 9 (rad) to several 
100 rad: 100 rad = 1 (Gy)] compared to those used therapeutically (5 000 to 
25 000 rad). High 131I dosages have the characteristic to terminate the cell’s 
potential to divide and because of this characteristic eliminate the cell’s 
potential for causing malignancy. Low radiation dosages on the other hand 
may stimulate both malignant and benign growth.  
 
131I as a treatment option has various advantages but also disadvantages, 
namely: 
(i) Delay in controlling the hyperthyroidism, especially in cases of 
inadequate treatment dosage, as well as in some patients who are 
extraordinarily resistant to sodium iodide (131I). 
(ii) The incidence of hypothyroidism after 131I treatment as the years goes 
on, but this is also a disadvantage of surgery (Safa & Skillern 
1975:673). 
Another disadvantage of 131I treatment is that radiation thyroiditis can occur, 
although rare with release of stored thyroid hormone into the circulation after 
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131I therapy (Meier et al. 2002:857). The release of stored thyroid hormone 
into the circulation can worsen the hyperthyroid state of Graves’ disease 
causing thyroid storm. 
 
131I treatment for Graves’ disease has several advantages, including that 
patients can be treated on an outpatient basis; recurrence rate is small; and 
the costs are low for patients as well as for the community (Holm et al. 
1982:106). 131I as treatment option for Graves’ disease is used to treat most 
Graves’ disease patients at the UNMD. 131I treatment therapy has resulted in 
decreased mortality and morbidity of patients with Graves’ disease (Safa & 
Skillern 1975:673). The research available indicates no harmful effects 
associated with 131I therapy in children and adolescents, as well as on 
subsequent fertility, birth history of patients, health status and reproductive 
history (Holm et al. 1982:106). 
 
Nordyke and Gilbert (1991:414) constructed a dosage-cure curve as a guide 
to individualised treatment. This dosage-cure curve demonstrated that a 185 
MBq 131I therapeutic dosage will have a cure rate of 70% and 370 MBq will 
have an 87% cure. From this dosage-cure curve the conclusion can be drawn 
that the higher 370 MBq therapeutic dosage has a higher cure and the better 
choice for a fixed dosage treatment. The aim of the treatment dosage is 
always to provide a cure for Graves’ disease. This cure will be provided by 
the most accurately calculated treatment dosage. There are various factors 
that should be considered if the initial treatment dosage fails, for example the 
patient’s direct cost in rands, time from work, and the patient morbidity are 
increased. 
 
The maximum RAIU value is important for the calculation of the correct 131I 
therapeutic dosage to treat Graves’ disease.  In the case of euthyroid 
patients, the maximum RAI uptake in the thyroid is between 24 and 48 hours 
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(Van Isselt et al. 2000:610). With Graves’ disease the maximum RAI uptake 
in the thyroid may reach a peak earlier than 24 hours. Therefore it is 
suggested that an RAIU is taken before 24 hours, at a relatively early stage 
(4-6 hours), as well as at 24 hours. There is “rapid iodine turnover” in the 
case where the 5-hr/24-hr uptake ratio is >1. Van Isselt et al. (2000:610) 
defined the “rapid turnover” process of iodine as a short effective half-life 
(Teff) of 131I and a diminished therapeutic effect. In the cases where “rapid 
turnover” is present it is necessary to increase the 131I therapeutic dosage as 
the 24-hr would give a low uptake value.  As the 24-hr RAIU value is low and 
does not indicate the peak of the turnover it would lead to an undertreatment 
of this patient. The 6-hr RAIU value would therefore indicate the peak and 
maximum point of iodine turnover and could be used to adjust the treatment 
dosage.  When using the 24-hr RAIU value to calculate the 131I therapeutic 
dosage for a “rapid turnover” the Graves’ disease patient may be 
undertreated if there is risk of recurrence of disease. 
 
The investigation conducted by Van Isselt et al. (2000:614) showed that 9% 
of the Graves’ disease patients used in their study had “rapid turnover”. 
These patients could have received inappropriate 131I therapy dosage if only 
the 24-hr RAIU value was used to calculate therapeutic dosage 
(administration activity). At the UNMD the 24-hr RAIU value was used for 
calculation dosage for Graves’ disease. Yet in our study the percentage of 
the Graves’ disease patients with “rapid turnover” was determined as well as 
the results of 131I therapeutic treatment. This information gave an indication 
which of the 6-hr or the 24-hr RAIU value is best to calculate the 131I 
therapeutic dosage. 
 
Van Isselt et al. (2000:615) recommend that the 131I therapeutic treatment 
should be given as soon as possible after the 131I RAIU test is finished, 
because of the intra-individual changes in both the 131I uptake and iodine 
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turnover in the thyroid gland. The 131I therapeutic dosage for Graves’ disease 
is administered the same day as the 24-hr 131I RAIU test is done at the 
UNMD (not necessarily done for patient convenience and cost-effectiveness). 
 
It is always important to consider the radiation burden to the patient, therefore 
the calculation of the 131I treatment dosage should be done with great 
precision (Van Isselt et al. 2000:614). Therefore it is essential that the 131I 
RAIU procedure be optimised for the calculation for a Graves’ disease patient 
therapy dosage. According to Safa and Skillern (1975:675), 131I therapy is 
currently considered as the best form of treatment for Graves’ disease. The 
UNMD also considers 131I therapy as the best treatment option for Graves’ 
disease. 
 
 
2.17  GUIDELINES FOR TREATMENT 
 
RAI is the ideal treatment option in patients with relapsed Graves’ disease 
(Hennemann et al. 1986:1371). In very large goitres the first optimal choice is 
subtotal thyroidectomy, as RAI is of limited value. Very large goitres are also 
treated with thyroidectomy at the UNMD. Holm et al. (1982:106) recommend 
that the optimal treatment choice for patients with large goitres and 
progressing eye symptoms is thyroidectomy. Surgery is also recommended in 
those few cases in which malignancy is suspected. 
 
 
2.18  131I TREATMENT DOSAGE 
 
Chapman and Maloof (1955:278) state that there are three main factors that 
influence the effects of RAI on the thyroid and thus the dosage received by 
the thyroid: 
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    The absorbed dosage received by the thyroid gland physically. 
    The dispersion of RAI within the thyroid. 
    The thyroid cell sensitivity to RAI. 
The authors also point out that there is a variation in the dispersion of 
radioactivity in the thyroid (Chapman & Maloof 1955:281). This factor can 
explain the varied responses of patients to a similar dosage of the 
radionuclide. 
 
 
2.19 ADEQUATE ABSORBED ACTIVITY FOR THE 
INTRATHYROID TISSUE 
 
The calculation of the precise and accurate therapeutic dosage for Graves’ 
disease is consequential, since the damage of thyroid follicular cells by RAI to 
a large extent depends on the absorbed dosage from 131I administered (De 
Bruin et al. 1994:508). According to Alexander and Larsen (2002:1073), an 
absorbed activity of 296 MBq 131I in the thyroid gland is an efficient treatment 
option for most patients with Graves’ disease. The UNMD uses the RAIU test 
for the calculation of the 131I therapeutic dosage for Graves’ disease patients 
so that the intrathyroid absorbed activity received is 296 MBq 131I. The scope 
of 131I absorbed activity per g of thyroid tissue for the effective treatment of 
Graves’ disease as given by the EANM (2003:30) is from 2.2-3.0 MBq/g up to 
6.0-7.0 MBq/g. The conclusion that can be drawn is that a thyroid weighing 
50g should receive a 131I therapeutic dosage of between 110 MBq and 350 
MBq for the effective treatment of Graves’ disease. A Graves’ disease patient 
who receives an intrathyroid absorbed activity of more than 350 MBq has 
received unnecessary 131I therapeutic activity to the thyroid gland. The UNMD 
considers a Graves’ disease patient who received an intrathyroid absorbed 
activity of more than 350 MBq to have received a less accurate therapeutic 
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dosage. In short, when calculating the different therapeutic dosages with the 
6-hr or the 24-hr 131I RAIU values the intrathyroid absorbed activity should not 
be more than 350 MBq of 131I, otherwise the patient will receive unnecessary 
131I activity to the thyroid gland. 
 
In a normal person who received 131I orally for RAIU, the measured uptake 
increases progressively and then reaches a plateau between 18- and 24-hr 
after intake (Harbert & Da Rocha 1984:9). Van Isselt et al. (2000:609) point 
out that the 24-hr 131I RAIU value is traditionally used for the calculation of the 
131I administration activity for therapeutic dosage. The 24-hr 131I RAIU value is 
indicated by Van Isselt et al. (2000:609) to be the most efficient for the 
calculation of the 131I administration activity for patients with Graves’ disease. 
Wagner et al. (1995:598) also suggest that the value of the 24-hr 131I RAIU is 
highly recommended for the calculation of the therapeutic dosage for Graves’ 
disease.  
 
The 24-hr 131I RAIU value is considered the favourite choice for therapeutic 
dosage calculations, because “rapid turnover” of 131I in the first two hours and 
a lower 24-hr RAIU is rare (Harbert & Da Rocha 1984:12). Graves’ disease 
(hyperthyroidism) can show different characteristic curves and turnover points 
of thyroid uptake after 131I oral administration (see Figure 1.1). The 24-hr 
RAIU value is usually higher than the 6-hr RAIU value, therefore the 24-hr 
RAIU value is regarded as the better choice, as the optimal thyroid uptake 
percentage needs to be determined for the effective administered therapeutic 
activity calculation. It would be interesting to see when the 24-hr 131I RAIU 
value is used with the administration activity calculated by the 6-hr 131I RAIU if 
the intrathyroid absorbed dosage received will still be 296 MBq. The following 
equation will be adjusted for this purpose in the data analysis (CAA = 
calculated administration activity; IAA = intrathyroid absorbed activity): 
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CAA  from 131I RAIU value     =                            Aimed IAA 
                                                       % (value) of the 6- or 24-hr 131I RAIU 
  
  
2.20 HYPOTHYROIDISM RELATED TO 131I TREATMENT 
 
According to Nordyke and Gilbert (1991:411), during the early years of the 
development of 131I therapy there was a failure to recognise that most 
Graves’ disease patients will eventually become hypothyroid regardless of 
the therapeutic dosage selected. Hypothyroidism has a cumulative incidence 
of as high as 70% after RAI treatment (Glennon, Gordon & Sawin 1972:721). 
Glennon et al. (1972:722) report that there is a variation in the incidence of 
hypothyroidism after 131I treatment for hyperthyroidism. Treating hyperthyroid 
patients with low dosages of 131I causes a decrease in first-year incidence of 
hypothyroidism, but overall the cumulative incidence may not be decreased 
(Glennon et al. 1972:723). 
 
Gunasekera, Hesslewood, Notghi and Harding (2000:21) also state that the 
occurrence of hypothyroidism after 131I treatment is believed to be 
proportional to the dosage. The conclusion was also made by Gunasekera et 
al. (2000:21) that hypothyroidism is initially lower in patients receiving activity 
less than 200 MBq, but this resulted in four-fold repeat therapy dosages 
compared to 400 MBq. The dosage of 131I delivered to the thyroid gland when 
treating Graves’ disease patients correlates with the incidence of 
hypothyroidism after treatment (Holm et al. 1982:106). The elimination of 
Graves’ disease will only be prolonged with low-dosage 131I therapy without 
any ultimate reduction in the incidence of hypothyroidism. Compared to the 
low-dosage 131I therapy the higher 131I treatment dosages result in higher 
cure rates and a decreased need for retreatment. Higher 131I treatment 
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dosages are reported to increase the incidence of hypothyroidism after 
treatment for Graves’ disease.  
 
Currently the risk of developing thyrotoxic crisis after 131I therapy is almost 
insignificant (Holm et al. 1982:106). Nowadays these patients can easily be 
identified and pretreated with antithyroid drugs and/or beta blockers. 
Corticosteroids in collaboration with antithyroid drugs and beta blockers can 
be used in cases where potential for thyrotoxic crisis was not detected before 
131I treatment. 
 
Some researchers have suggested that Graves’ disease patients are 
optimally treated by a single 131I ablative dosage to the thyroid, arguing that 
the aim is eliminating hyperthyroidism; that larger therapy dosages 
accomplish it with more certainty; and that hypothyroidism will inevitably 
develop (Nordyke & Gilbert 1991:411). At the UNMD a large single 131I 
ablative dosage is given to a Graves’ disease patient with the aim to 
completely eliminate this hyperthyroid state. 
 
Hypothyroidism after 131I treatment in Graves’ disease seems to continue to 
develop at a steady rate, even after 10 years (Hennemann et al. 1986:1370). 
These researchers also suggest that, when this inevitable hypothyroid state 
has developed, it is managed under the control of the physician (Nordyke & 
Gilbert 1991:411). Therefore if all Graves’ disease patients eventually 
became hypothyroid after 131I therapy, the goal of achieving a permanent 
state of normal thyroid function is unrealistic. 
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2.21 SUMMARY AND CONCLUSION 
 
The 131I RAIU test can be used to distinguish Graves’ disease from other 
thyroid diseases (McDougall 1991:79). 131I is predominantly used for the 
RAIU measurement and 131I is also organified in the thyroid that makes it 
ideal for thyroid functional testing (Wagner et al. 1995:598). Hence, the 131I 
RAIU test provides diagnostic information about the thyroid function (Grayson 
1960:397).  131I is not only used for the RAIU tests, but also for the treatment 
of Graves’ disease. Consequently 131I is a radionuclide that can be used for 
RAIU testing, as well as for the treatment of Graves’ disease and it is used for 
these purposes at the UNMD. 
 
There are various treatment options for Graves’ disease, including antithyroid 
drugs, thyroidectomy and RAI (Lind 2002:453). According to Safa and Skillern 
(1975:675), 131I therapy may not be the perfect form of treatment for Graves’ 
disease, but it is still a much better option compared to surgical or antithyroid 
drug therapy. At the UNMD RAI is the primary treatment option for Graves’ 
disease and the RAIU test is used for the calculation of the treatment dosage. 
The RAIU test procedure used at the UNMD is the RAIU test procedure 
prescribed by the IAEA (see paragraph 1.1.4). 
 
The method of therapy dosage calculation for Graves’ disease patients at 
different institutions may vary (Hayes et al. 1990:520). At the UNMD the 131I 
RAIU test is used to determine the percentage uptake of iodine by the thyroid 
gland and then a treatment dosage is calculated for above normal uptake 
percentages. The result is that 131I measurement aids in calculating the 
amount of 131I to be administered for the therapy of hyperthyroidism due to 
Graves’ disease. 
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At the UNMD a 6- as well as a 24-hr RAIU value is obtained to calculate the 
therapeutic dosage (administration activity) for Graves’ disease. Hayes et al. 
(1990:519) have a theory that the early (6-hr) RAIU value alone can be used 
to calculate the 131I therapeutic dosage for Graves’ disease. The 3- to 6-hour 
RAIU value is supposed to be comparable with the 24-hr RAIU value for the 
131I therapeutic dosage calculation. McDougall (1991:86) indicates that there 
is a possibility for same day diagnosis, dosage calculation and treatment of a 
Graves’ disease patient, as there are some reports of a correlation between 
the 6-hr and the 24-hr RAIU value. If this correlation is applicable at the 
UNMD and a 6-hr RAIU value only is needed to calculate the 131I therapeutic 
dosage for Graves’ disease patients, a same day diagnosis will also be 
possible. The same day diagnosis will lead to a decrease in hospital stay and 
patient expenses, as the patient will not have to return the following day to 
obtain a 24-hr value for the RAIU test. 
 
The maximum RAIU value is important for the calculation of the correct 131I 
therapeutic dosage to treat Graves’ disease. When “rapid turnover” in the 
thyroid is present, the 6-hr RAIU value will be higher than the 24-hr RAIU 
value and will present the time of maximum thyroid uptake percentage (Van 
Isselt et al. 2000:610). The difference between the 6- and 24-hr values should 
be determined in all patients. 
 
The next chapter, Chapter 3, entitled “Investigation design and methods” will 
explain the empirical approach and provide a description of the methodology 
that was used to achieve the aim of the investigation.  
 
 
 
 
 
 48 
CHAPTER 3 
 
 
INVESTIGATION DESIGN AND METHODS 
 
 
3.1 INTRODUCTION 
 
Chapter 3 provides information on the investigation design* and methods to 
seek answers to the questions stated in paragraph 1.2.1. This specific design 
enables the investigator to obtain sufficient information and answers. The 
investigation design and methods applied will be discussed next. 
 
 
3.2 INVESTIGATION DESIGN 
 
The correlation of the 6-hr and 24-hr 131I RAIU values of patients with Graves’ 
disease referred to the UNMD in the Free State was investigated. The study 
design was two-fold (see Figure 1.2): First a literature review was carried out 
to determine the significance of both the 6-hr and 24-hr 131I RAIU values in 
patients with Graves’ disease. Second, a retrospective investigation was 
conducted to analyse and compare the 6-hr and 24-hr RAIU values of 
patients diagnosed with Graves’ disease referred to the UNMD during 2004 
and 2005. 
 
 
 
• The investigation design implies the plan for collecting and utilising data so that the              
required information can be obtained with adequate accuracy to test a theory. 
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3.3 INVESTIGATION GROUP 
 
The investigation group included patients with confirmed Graves’ disease 
referred to the UNMD during 2004 and 2005. The patients included in the 
investigation group, both male and female, were from different race groups 
ranging from 15-75 years in age. 
 
 
3.4 PROCEDURE 
 
The paragraphs that follow focus on the procedure of the investigation and 
provide a description of the methods used. Aspects of the investigation 
design which include the retrospective data retrieval, the inclusion and 
exclusion of patient data, as well as the experimental methods used, will 
receive attention. 
 
3.4.1 Retrieval of patient data 
All the files of patients who had undergone 131I RAIU thyroid tests to diagnose 
Graves’ disease during 2004 and 2005 at the UNMD were obtained. At the 
Universitas Hospital Graves’ disease is confirmed by a suppressed TSH, 
elevated T4 or T3, a diffuse increased uptake of 99mTc-pertechnetate, and an 
increased 6-hr and 24-hr 131I RAIU value. Patients who did not meet the 
above criteria of diagnosis of Graves’ disease were excluded from the 
investigation group.  
 
3.4.2 Inclusion criteria 
The investigation focused on Graves’ disease specifically, not on other 
thyroid diseases. The inclusion criteria included patients with only Graves’ 
disease who had undergone both a 6-hr and 24-hr 131I RAIU. 
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3.4.3 Exclusion criteria 
In order to increase the validity of the investigation, all factors that can 
influence the accuracy of the 131I RAIU thyroid test were excluded. The 
exclusion criteria for the patients from the investigation were the following: 
 Patients who received antithyroid medication or any other medication 
that could influence the RAIU values obtained. 
 Patients who received an iodine-containing X-ray examination during 
the period of the 6- and 24-hr 131I RAIU examination. 
 The presence of nodules on the 99mTc-pertechnetate scintigraphy of 
patients who had received 6- and 24-hr 131I RAIU examination during 
2004 until the end of 2005.  
 
As part of the exclusion phase of the study, it was important to determine 
which medication the patients used at the time of their 6- and 24-hr 131I RAIU 
examination and whether this had an influence on the uptake values 
obtained. Appendix C:5 shows in table form relevant materials and 
medication that should be excluded for a delayed period before an RAIU 
examination. All the medications used by patients visiting Universitas hospital 
is listed on a computer file system. The Graves’ disease patient list of 
medications used from 2 weeks before and during the time period of the 
RAIU test was noted on data sheets. The information used on the data sheets 
was used to exclude patient for investigation group.  
 
The medication and antithyroid drugs listed in Appendix C:5 had an influence 
on the 6- and 24-hr 131I RAIU value. A short summary of the characteristics of 
these antithyroid drugs and medication was made (see Appendix C:6). The 
medication used by some of the patients that influenced the accuracy of the 
131I RAIU test from the above table, included atenolol (n=1), carbimazole 
(n=1), propranolol (n=13) and thyroxine (n=2).  
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Patients who had received an iodine-containing X-ray examination two weeks 
prior to the 6- and 24-hr 131I RAIU test were also excluded. There was only 
one patient who had undergone Magnetic Resonance Imaging (MRI) of the 
orbits with iodine contrast administration. This patient was excluded because 
of this examination. 
 
Another exclusion factor was the presence of nodules on the 99mTc-
pertechnetate scintigraphy. When the pertechnetate scintigraphy results were 
evaluated, it was found that out of the 178 patients, 33 were multi-nodular; 
one had Plummer’s disease; one had Marine-Lenhardt syndrome; two had 
had lobes removed; and one had toxic autonomic adenoma. All these 
patients had to be excluded, as only Graves’ disease patients were included 
and other thyroid diseases would have had an influence on the accuracy of 
the 131I RAIU values for this specific investigation. 
 
The original investigation group consisted of 178 patients and 54 patients 
were excluded. Two of the 54 patients displayed to two of the exclusion 
criteria.  
 
 
3.5 ANALYSIS 
 
The Department of Biostatistics of the UFS, were consulted for 
recommendations regarding the management of data and the processing of 
results. Results were summarised by means and standard deviations or 
medians and percentiles for continuous data and frequencies and 
percentages for categorical data. The 95% confidence intervals were 
constructed for the difference in mean and median values. The Spearman 
correlation coefficient was used to determine the correlation between different 
variables. A regression analysis was performed between the 6-hr and 24-hr 
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131I RAIU values. An analysis was also made of the different transit patterns 
of Graves’ disease patients at the UNMD. This analysis of the transit patterns 
was done to determine how many of these patients had rapid turnover of 
iodine in their thyroid glands. 
 
Graves’ disease is treated effectively with an absorbed intrathyroid dosage of 
296 MBq (Alexander & Larsen 2002:1073). As previously mentioned, the 
following equation was used to determine the 131I administration therapeutic 
activity that was given according to the 6-hr or 24-hr RAIU% (Alexander & 
Larsen 2002:1074): 
 
CAA  from 131I RAIU value     =                            Aimed IAA 
                                                       % (value) of the 6- or 24-hr 131I RAIU 
            
131I thyroid treatment activity that is not absorbed in the thyroid gland should 
be limited, because 131I is fairly expensive and should not be wasted (cost-
effectiveness). Keeping cost-effectiveness in mind, it was of value to see what 
the difference between the administered 131I activity using the 6-hr or 24-hr 
131I RAIU would be. It was also of value to see when the 24-hr 131I RAIU value 
was used with the CAA by the 6-hr RAIU value if the IAA was still between 
the recommended range of 110 MBq to 350 MBq. Graves’ disease patients 
showed increased 6-hr and 24-hr 131I RAIU values, as well as an increased T4 
value. A comparison was also made between the 6-hr and 24-hr 131I RAIU 
values to see if there was any correlation with the T4 values of Graves’ 
disease patients. 
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3.6 ETHICAL ASPECTS 
 
Informed consent was obtained from the Ethics Committee of the UFS 
(ETOVS Nr. 40/06) and the Central University of Technology (CUT) after 
evaluation of the investigation protocol. Since the investigation was done 
retrospectively, consent was obtained from the chief specialist and the 
director of the Universitas Hospital. There was no need to obtain consent 
from the RCC, as the 131I uptake measurements done at the UNMD falls 
within the RCC rules and regulations.   
 
 
3.7 CONCLUDING REMARKS 
 
This chapter focused on the investigation design, methods, as well as the 
process followed. The different aspects of the design were addressed and the 
method of collecting data received attention. In the next chapter, the 
statistical results and findings of the investigation will be presented. 
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CHAPTER 4 
 
 
RESULTS AND FINDINGS 
 
 
4.1 INTRODUCTION 
 
In this chapter the results of the investigation group with regard to the 
following areas will be reported on: The transit patterns; how the 6-hr and 24-
hr 131I RAIU values correlate with each other and the T4 values and the 
correlation between the 6-hr and 24-hr RAIU CAA (therapy dosage) and their 
correlation with T4. The results of the IAA that will be received by the thyroid 
when the 24-hr RAIU value is used with CAA by 6-hr RAIU value and if the 
IAA falls between the recommended range of 110 MBq to 350 MBq are 
provided. The TSH values of the investigation group was analysed to see if 
any significant statistical information was obtained. 
 
 
4.2 RESULTS 
 
The original group investigated consisted of 178 Graves’ disease patients 
before patients were excluded due to the specific criteria mentioned. After the 
exclusion criteria had been applied, the final group investigated consisted of 
124 Graves’ disease patients. The age of the investigation group ranged 
between 15 and 75 years (see Table 4.1).  
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Table 4.1: Summary of age 
n Lower Median Upper  Minimum Maximum 
 Quartile   Quartile (Min)  (Max)  
 (Q)    (Q)  years  years 
124 30  39  48  15  75  
     
The group mainly consisted of females, whereas the males were only 14.5% 
of the total investigation group. The race of the investigation group consisted 
of black, white and coloured (see Table 4.2).  
 
Table 4.2: Gender and race of investigation group 
     n  % of total group 
Gender 
Male       18   14.5 
Female    106   85.5 
 
Race 
Black       87   70.2 
White       28   22.6 
Coloured        9     7.3 
 
In the next section the results of the 6-hr and 24-hr 131I RAIU values of the 
investigation group are provided. Comparison and analysis of the 6-hr and 
24-hr 131I RAIU values will also be scrutinised. 
 
 
4.3 THYROID UPTAKE VALUES 
 
This section reports on the 6- and 24-hr 131I RAIU values and the related 
statistics of the investigation group. Figure 4.1 demonstrates the values for 
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the 6- and 24-hr RAIU of the investigation group (n=124). In Figure 4.1 it can 
be seen that the 24-hr RAIU values tended to fall more in the higher 
percentage range. On the other hand, the 6-hr RAIU values tended to fall in 
between the lower and higher % values. 
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Figure 4.1: Comparison between 6-hr and 24-hr RAIU  values 
 
The analysis of the 6- and 24-hr RAIU values indicated that the median of the 
6-hr RAIU values was 67.5% and the median of the 24-hr RAIU values was 
80% (see Table 4.3).  
 
Table 4.3: Summary of the 6-hr and 24-hr RAIU values 
  n Lower Median Upper  Min  Max 
   Q    Q  (%) (%) 
 6-hr RAIU 124 51.5  67.5  78  11.9   99     
24-hr RAIU 124 69  80  87  39 100      
 
Regression analysis was done to see if there was any relation between the 6-
hr RAIU and the 24-hr RAIU values (see Figure 4.2). Figure 4.2 shows a 
strong positive linear relationship between the 6-hr RAIU and the 24-hr RAIU 
values (Pearson correlation coefficient obtained r=0.82).  
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Figure 4.2: Pearson correlation analysis between the 6-hr and the 24-hr 
RAIU values 
 
Table 4.4 summarises the difference between the 6-hr and 24-hr RAIU 
values. The limits of agreement (the range within which the central 95% of 
data is expected to lie) is –38 to 7. 
 
Table 4.4: Difference between the 6-hr and the 24-hr RAIU values  
n Lower Median Upper  Min  Max  
 Q    Q   (%)  (%) 
124 -20.35  -13  -7  -45  14.9 
   
Table 4.5 demonstrates the difference between the 6-hr and 24-hr RAIU 
values.  A  -5% or smaller difference between the 6-hr and 24-hr RAIU values 
was only present in 11 of the 124 Graves’ disease patients. 
 
 
 
 
    Regression line 
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Table 4.5: Summary of the difference between the 6-hr and the 24-hr 
RAIU values (n=124) 
Dif. between 6-hr Frequency  Percent       Cumulative    Cumulative 
and 24-hr RAIU     Frequency      Percent 
values 
-45.9 to -40    2    1.6      2       1.6 
-39.9 to -35    4    3.2      6       4.8 
-34.9 to -30    1    0.8      7       5.7 
-29.9 to -25    9    7.3    16     13.0 
-24.9 to -20  18  14.5    34     27.4 
-19.9 to -15  19  15.3    53     42.7 
-14.9 to -10  26  20.9    79     63.7 
-9.9 to -5.1  20  16.1    99     79.8 
-5 to 0   11    8.9  110     88.7 
0 to 5     9    7.3  119     96.0 
5.1 to 10    2    1.6  121     97.6 
10.1 to 15    3    2.4  124   100.0 
  
 
4.4 TRANSIT PATTERNS 
 
The transit patterns give an indication whether the 6-hr RAIU value will only 
be effective to determine the 131I therapy dosage for Graves’ disease. The 
transit patterns of the investigation group for the 6- and 24-hr RAIU values 
are given in Table 4.6. In 11.3% (n=14) of the investigation group the 6-hr 
RAIU value was higher than the 24-hr RAIU value. The 24-hr RAIU value was 
higher in 88.7% (n=110) of the investigation group higher than the 6-hr RAIU. 
The transit patterns show that in a very few Graves’ disease patients, the 6-hr 
RAIU values will be higher than the 24-hr RAIU values. 
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Table 4.6: Transit patterns 6-hr and 24-hr RAIU values 
Group  Frequency  Percent  
   (ƒ)   (%)    
6>24    14   11.3    
6<24   110   88.7  
 
 
4.5 CORRELATION ANALYSIS BETWEEN 6-HR RAIU AND 
T4 VALUES 
 
Regression analysis was done to see if there was any relation between the 6-
hr RAIU and the T4 values (see Figure 4.3). Figure 4.3 shows a moderate 
positive linear relationship between the 6-hr RAIU and the T4 values (Pearson 
correlation coefficient obtained r=0.53; Spearman correlation coefficient 
r=0.57).  
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Figure 4.3:  Pearson correlation analysis between 6-hr RAIU and T4 
values 
 
    Regression line 
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The median for the 6-hr RAIU values was 67.5% and the median for the T4 
values was 67.3%. Table 4.7 shows that the median % values for the 6-hr 
RAIU and T4 lie very close together.  
Table 4.7: Summary of 6-hr RAIU values with T4 values for the 
investigation group (n=124) 
Variable Lower Median  Upper        Min  Max 
  Q    Q                        
6-hr RAIU 51.5  67.5    78  11.9    99 
(%) 
T4 (µg/dl) 46.5  67.3  105.8  15  163.1  
 
 
4.6 CORRELATION ANALYSIS BETWEEN THE 24-HR RAIU 
AND T4 VALUES 
 
Regression analysis was done to see if there was any relation between the 
24-hr RAIU and the T4 values (see Figure 4.4). Figure 4.4 shows a weak 
positive linear relationship between the 24-hr RAIU and the T4 values 
(Pearson correlation coefficient obtained r=0.39; Spearman correlation 
coefficient r=0.46). 
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Figure 4.4: Pearson correlation analysis between 24-hr RAIU and T4  
values       
    Regression line 
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The median for the 24-hr RAIU values was 80% and the median for the T4 
values of the same patients was 67.3%. Table 4.8 shows that the median % 
values for the 24-hr RAIU values and T4 lie very far apart, with the median of 
the 24-hr RAIU values much higher.  
 
Table 4.8: Summary of 24-hr RAIU values with T4 values for the 
investigation group (n=124) 
Variable Lower Median Upper      Min  Max  
  Q    Q              
24-hr  
RAIU (%) 69  80    87  39  100  
T4 (µg/dl) 46.5  67.3  105.8  15  163.1  
 
 
4.7 CORRELATING THE VALUES OF THE 6-HR AND THE 24-
HR CAA VALUES 
 
Figure 4.5 shows the different values for the 6-hr and 24-hr RAIU CAA for the 
investigation group (n=124). When a closer look is taken at Figure 4.5, it 
shows that the 6-hr RAIU CAA values are much higher than those of the 24-
hr RAIU CAA values. The 24-hr RAIU CAA values lie closer together, 
whereas the 6-hr RAIU CAA values lie further apart. The 6-hr RAIU CAA has 
the highest value and the 24-hr RAIU CAA has the lowest value. Overall the 
6-hr RAIU CAA has the highest values and the 24-hr RAIU CAA has the 
lowest values. 
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Figure 4.5: Comparison between 6- and 24-hr RAIU CAA.  
 
Table 4.9 gives a summary of the 6-hr RAIU CAA and the 24-hr CAA values 
for the investigation group (n=124). Table 4.9 confirms what was seen in 
Figure 4.5 about the minimum and the maximum values of the 6-hr and 24-hr 
RAIU CAA values. The median of the 6-hr RAIU CAA values was 438.5 MBq 
and the median of the 24-hr RAIU CAA was 370 MBq. Table 4.9 shows that 
the 6-hr CAA values had a higher median than the 24-hr CAA values. 
 
Table 4.9: Summary of 6-hr RAIU CAA values with the 24-hr RAIU CAA 
values for the investigation group (n=124) 
 
Variable Lower Median   Upper   Min  Max 
  Q    Q            
 6-hr (MBq) 380  438.5      564  299  2487  
24-hr (MBq) 344  370      429  296  759  
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4.8 DIFFERENCE BETWEEN 6-HR AND THE 24-HR RAIU 
CAA 
 
The results are given below of the difference between the 6-hr and 24-hr CAA 
values. Table 4.10 summarises this specific data analysis as stated in this 
section.  
 
Table 4.10: Difference between the 6-hr and the 24-hr RIAU CAA values 
for the investigation group (n=124) 
Variable Lower Median Upper  Min  Max        
  Q    Q                 
 Dif. 6-hr 28   76  168.5  -98  1739 
 and 24-hr 
CAA (MBq) 
 
 
4.9 INTRATHYROID ABSORBED ACTIVITY 
 
Figure 4.6 shows the values for the patient IAA calculated when the 24-hr 
RAIU values were used with the CAA by the 6-hr RAIU values. 
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Figure 4.6: Patient calculated IAA when 24-hr RAIU value is used with                
  CAA by the 6-hr RAIU value 
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The most effective intrathyroid absorbed dosage received to treat Graves’ 
disease should be between 110 MBq and 350 MBq. Table 4.11 demonstrates 
the statistics when the 24-hr RAIU value is used with the CAA by the 6-hr 
RAIU value. The minimum value for the IAA calculated when the 24-hr RAIU 
value is used with the CAA by the 6-hr RAIU value is 238 MBq. The minimum 
IAA for this calculation therefore falls within the recommended range of 110-
350 MBq. The maximum IAA on the other hand, is much higher than the most 
effective IAA 985 MBq. The median for this specific calculated IAA is 357.5 
MBq. Therefore the median of the 24-hr value used with the CAA by the 6-hr 
RAIU value does not fall within the recommended range. 
  
Table 4.11: IAA for the investigation group (n=124) 
Variable Lower Median  Upper   Min  Max   
  Q    Q              
IAA  321.5  357.5  411.5  238  985     
(MBq) 
 
Table 4.12 illustrates how many of the investigation group (n=124) would 
have received more activity than the recommended range (110-350Mq). Fifty 
eight (46.8%) of the Graves’ disease patients would receive IAA within the 
recommended range. More than 53.3% of the investigation group would 
receive a higher IAA than the recommended range if the 24-hr RAIU was 
used with the CAA at the 6-hr RAIU. 
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Table 4.12: Amount of activity (act.) exceeding the recommended range 
of 110-350 MBq 
Amount of act. Frequency  Percent       Cumulative     Cumulative 
exceeding       Frequency        Percent 
recommended  
range (MBq) 
0   58  46.8      58    46.8 
1-20                   8    6.4      66    53.3 
21-40    15  12.1      81     65.3 
41-60   11    8.9      92    74.2 
61-80    7    5.6      99    79.8 
81-100  5     4.0   104    83.9 
101-120  5    4.0   109    87.9 
121-140  2    1.2   111    89.5 
141-160  2    1.2   113    91.1 
161-180  2    1.2   115    92.7 
181-200  0    0   115    92.7 
201-220  1    0.8   116    93.6 
221-240  1    0.8   117    94.4 
241-260  1    0.8   118    95.2 
261-280  1    0.8   119    96.0 
281-300  1    0.8   120    96.8 
301-320  1    0.8   121    97.6 
321-340  1    0.8   122    98.4 
341-420  0    0   122    98.4 
421-440  1    0.8   123    99.2 
441-620  0    0   123    99.2 
621-640   1    0.8   124  100 
 
 66 
4.10  CORRELATING THE CAA BY THE 6-HR RAIU VALUES 
WITH T4 VALUES 
 
Figure 4.7 shows the regression analysis between the CAA by the 6-hr RAIU 
values and T4 values. A moderate negative linear relationship was obtained 
(Pearson correlation coefficient obtained r=-0.43; Spearman correlation 
coefficient r=-0.58). 
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Figure 4.7: Correlating the CAA by 6-hr RAIU values with T4 values 
 
Table 4.13 illustrates the summary statistics between the CAA by the 6-hr 
RAIU values and T4. The median of the CAA by the 6-hr RAIU was 438.5 
MBq and the median of T4 values in the same Graves’ disease patients was 
67.3 µg/dl. Table 4.13 also shows that the median for the CAA by the 6-hr 
RAIU is much higher than that of T4.  
 
    Regression line 
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Table 4.13: Summary of CAA by the 6-hr RAIU values with T4 values for 
the investigation group (n=124) 
Variable Lower Median  Upper  Min  Max 
  Q    Q 
6-hr CAA 380  438.5  564  299  2487         
(MBq) 
T4 (µg/dl)   46.5    67.3   105.8    15    163.1
            
 
4.11 CORRELATING THE CAA BY THE 24-HR VALUES WITH 
T4 VALUES 
 
Figure 4.8 shows the regression analysis between the CAA by the 24-hr RAIU 
value and T4 (Pearson correlation coefficient obtained r=-0.38; Spearman 
correlation coefficient r=-0.45). A moderate negative linear relationship was 
found between the CAA by the 24-hr RAIU values and the T4 values. 
 
y = -0.1497x + 138.27
R2 = 0.1464
0
50
100
150
200
0 200 400 600 800
CAA by 24-hr RAIU value (MBq)
T4
 
(m
ic
ro
 
g/
dl
)
CAA BY 24-HR RAIU%
AND T4
 
Figure 4.8: Pearson correlation analysis of the CAA by 24-hr RAIU 
values with T4 values  
 
    Regression line 
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The median of the CAA by the 24-hr RAIU was 370 MBq and the median of 
T4 was 67.3 µg/dl for the same Graves’ disease patients. Table 4.14 shows 
that the median for the CAA by the 24-hr RAIU is therefore also much higher 
than that of T4.  
 
Table 4.14: Summary of CAA by the 24-hr RAIU values with T4 values 
for the investigation group (n=124) 
Variable Lower Median Upper  Min  Max     
Q        Q 
CAA 24-hr   344  370  429  296  759  
(MBq) 
T4 (µg/dl)   46.5    67.3    105.8    15  163.1   
                 
 
4.12 THYROID-STIMULATING HORMONES 
 
The TSH values for the investigation group are not indicated as specific 
values (see Table 4.15). Therefore a correlation cannot be made between 
TSH and the 6-hr or 24-hr RAIU values.  
 
Table 4.15: TSH values as obtained from the investigation group 
(n=124) files 
TSH value   Frequency  Percent   
(ƒ)   (%)   
  0       1      1     
<0.01    99   80   
  0.01    10      8    
<0.02       1      1 
<0.03    10      8 
  0.03       1      1    
  0.06        1      1   
  0.43       1      1    
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4.13 SUMMARY 
 
The investigation group for the period 2004 till the end of 2005 consisted 
mainly of females (85.5%) and the race group that was the highest was 
blacks (70.2%). The comparison between the 6-hr and 24-hr RAIU median 
values shows that the 24-hr RAIU median values are higher than those of the 
6-hr RAIU median values. There is a strong positive relationship between the 
6-hr RAIU values and the 24-hr RAIU values (Pearson correlation coefficient 
obtained r=0.82). The limits of agreement (the range within which the central 
95% of data is expected to lie) are –38 to 7. 
 
The transit patterns showed that, in a very few (n=14) Graves’ disease 
patients, the 6-hr RAIU values were higher that the 24-hr RAIU values. A less 
than 5% value difference between the 6-hr and 24-hr RAIU values was only 
present in 11 of the 124 Graves’ disease patients. 
 
There was a moderate positive linear relationship between the 6-hr RAIU 
values and the T4 values (Pearson correlation coefficient obtained r=0.53; 
Spearman correlation coefficient r=0.57). A weak positive linear relationship 
was found between the T4 values and 24-hr RAIU values (Pearson correlation 
coefficient obtained r=0.39; Spearman correlation coefficient r=0.46). 
 
Overall, when calculating the CAA using the 6-hr RAIU value, the resultant 
value was higher than if the calculation was done using the 24-hr RAIU value. 
The median difference between the 6-hr and 24-hr CAA is 76 MBq. The CAA 
by the 6-hr RAIU values was used with the 24-hr RAIU values to calculate the 
IAA. 53.3% (n=66) of the investigation group would receive IAA higher than 
350 MBq when the CAA by the 6-hr RAIU values was used with the 24-hr 
RAIU values to calculate the IAA. 
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A moderate negative linear relationship was found between the CAA by the 6-
hr RAIU values and T4 values in the same Graves’ disease patients (Pearson 
correlation coefficient obtained r=-0.43; Spearman correlation coefficient r=-
0.58). Between the CAA by the 24-hr RAIU and T4 values a moderate 
negative linear relationship was found (Pearson correlation coefficient 
obtained r=-0.38; Spearman correlation coefficient r=-0.45). 
 
Chapter 4 provided the results and findings of the investigation that was 
undertaken. In the next chapter the results and findings of the investigation 
will be discussed and overall recommendations regarding the investigation 
will be supplied.  
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CHAPTER 5 
 
DISCUSSION AND RECOMMENDATIONS 
 
5.1 INTRODUCTION 
 
The investigation was undertaken in view of the responsibility that health 
workers have to reduce health care cost and improve health service. At the 
UNMD the 6- and 24-hour RAIU values are used to calculate the 131I 
treatment dosages for patients with Graves’ disease. According to the 
literature (see paragraph 1.1.9 on page 10) the highest 6- or 24-hr RAIU 
value will be the most effective to determine the correct 131I therapy dosage 
for Graves’ disease (Harbert & Da Rocha 1984:12). Yet, if it could be 
confirmed that the 6-hr RAIU value alone could be used, the hospitalisation 
cost and the patients’ own expenses could be reduced. In order to address 
the problem statement, the investigation sought to answer the following 
questions: 
 Is the 6-hr 131I RAIU value alone sufficient to calculate the optimal 
administered therapeutic activity for 131I for patients with Graves’ 
disease? 
 How do the 6-hr and 24-hr 131I RAIU values correlate with the T4 
values of patients with Graves’ disease?  
 What information will be obtained when the transit patterns in patients 
with Graves’ disease are analysed? 
 
The above-mentioned questions form the essence of this endeavour and the 
answers were searched for in the literature as well as in the outcome of the 
study. 
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Chapter 5 is a discussion of the main findings from both the literature and the 
investigation done. Salient points will be argued and connections between the 
reviewed literature and the results of the present study will be presented. 
Specific recommendations regarding further research will be given and the 
limitations of the investigation will receive attention. 
 
In Chapter 1 the investigation methodology and design were discussed and in 
Chapter 2 a literature review was carried out to determine the significance of 
the 6-hr and 24-hr RAIU values in patients with Graves’ disease. In the next 
section the validity of the investigation as well as how the information 
provided in Chapters 1 and 2 plays a role will be discussed. 
 
 
5.2 VALIDITY OF THE INVESTIGATION 
 
In Chapter 1 the investigation design was described as follows: First, a 
literature review was carried out to determine the significance of the 6-hr and 
24-hr RAIU values in patients with Graves’ disease. Second, a retrospective 
investigation was conducted to analyse and compare the 6-hr and 24-hr 
uptake values in patients with proven Graves’ disease in the Free State 
referred to the UNMD. The literature review was provided in Chapter 2. The 
sources that were consulted about aspects of the 6-hr and 24-hr RAIU values 
in patients with Graves’ disease were relevant published books and journal 
articles. The fact that the literature review was done by consulting published 
resources contributed to the validity of the retrospective research study. Prior 
to the final conclusion of the investigation a literature search was done again, 
but no new sources were found. 
 
As previously mentioned, only patients with proven Graves’ disease were 
included in the investigation group. The exclusion and inclusion criteria (see 
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paragraphs 3.4.1 and 3.4.2) for the investigation group were used to select 
patients with increased 6-hr and 24-hr RAIU values; increased T4 values; 
decreased TSH values; and an increased uptake on 99mTc thyroid 
scintigraphic scan. Patients with thyroid nodules were excluded from the 
investigation group, as nodules affect the physiological function of the normal 
thyroid gland and therefore influence the RAIU values. Graves’ disease 
patients that received medication that could have influenced the 6- and 24-hr 
RAIU values, as well as recent iodine-containing x-ray examinations were 
also excluded. The inclusion and exclusion procedure that was followed 
contributed to the validity of the investigation, as only proven Graves’ disease 
patients were included in the investigation group. 
 
 
5.3 LIMITATIONS OF THE INVESTIGATION 
 
The investigation was successful in achieving its overall goal and aim in 
answering the investigation questions. As the investigation was done 
retrospectively, some limitations occurred. The first limitation was that the 
Graves’ disease patients who had undergone the RAIU procedure might not 
have been done exactly under the same circumstances. An example of this 
inconsistency is that the radiographer who did the patient positioning might 
have been different, even though the same IAEA RAIU procedure was 
followed. The second limitation was that some of the Graves’ disease patients 
who had undergone the RAIU examination did not undergo a T4 blood test 
and had to be excluded. Third, the Graves’ disease patients at the Universitas 
Hospital did not undergo a blood test as a standard procedure to detect 
antibodies. The blood test that detects antibodies contributes to the accuracy 
of the diagnosis of Graves’ disease, even if this blood test does not assess 
thyroid function. Fourth, the TSH values of the Graves’ disease patients 
received from the files were abnormally low and fitted in with the diagnosis of 
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Graves’ disease. These values were not specific, however, and could not be 
used for statistical purposes. Even though the above-mentioned limitations 
did occur, they did not decrease the validity of the study. The limitations 
mentioned can be overcome by performing a prospective research study in 
the future. 
 
 
5.4 FINDINGS 
 
In this section the findings of the investigation will be discussed in relation to 
the investigation questions. After the inclusion and exclusion process, the 
final investigation group was made up out of 124 Graves’ disease patients. All 
the 124 confirmed Graves’ disease patients had increased T4 values, 
increased 6-hr and 24-hr RAIU values, increased uptake on the 99mTc 
scintigram, and decreased TSH values. The age range of the investigation 
group was between 15 and 75 years. The investigation group consisted of 
85.5% (n=106) females and 14.5% (n=18) males. The race of the 
investigation group consisted of 70% (n=87) blacks, 23% (n=28) whites, and 
7% (n=9) coloureds. 
 
The 6- and 24-hr RAIU values were compared. There was a large difference 
between the median of the 6-hr RAIU and the 24-hr RAIU values (67.5% vs. 
80%). There was a strong positive linear relationship between the 6-hr and 
24-hr RAIU values, but the difference between the 6-hr RAIU and 24-hr RAIU 
values is large (Pearson correlation coefficient obtained r=0.82). The limits of 
agreement (the range within which the central 95% of data is expected to lie) 
are –38 to 7.  
The transit patterns of the 6- and 24-hr RAIU values were also evaluated to 
determine which of the 6- or 24-hr RAIU values was most effective to 
calculate the 131I therapy dosage for Graves’ disease. Harbert and Da Rocha 
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(1984:12) state that the highest RAIU value 6- or 24-hr will be the most 
effective to determine the correct 131I therapy dosage for Graves’ disease. In 
only 11% (n=14) of the study group the 6-hr RAIU value was higher than the 
24-hr RAIU value. In 89% (n=110) of the study group the 24-hr RAIU value 
was higher than the 6-hr RAIU. The transit patterns show that in a very few 
Graves’ disease patients, the 6-hr RAIU value will be higher than the 24-hr 
RAIU. The transit patterns therefore demonstrate that the 24-hr RAIU value 
will be most effective to determine the 131I therapy dosage for Graves’ 
disease. A less than 5% value difference between the 6-hr and 24-hr RAIU 
values was only present in 11 of the 124 Graves’ disease patients. 
 
The median of the 6-hr RAIU and the T4 values differed only by 0.2% (67.5% 
vs. 67.3%). There was a moderate positive linear relationship between the 6-
hr RAIU values and the T4 values. The median of the 24-hr RAIU values was 
higher than the median of the T4 values (80% vs. 67.3%). There was a weak 
positive linear relationship between the 24-hr RAIU values and the T4 values. 
 
The CAA by the 6-hr RAIU values was compared with the CAA by the 24-hr 
RAIU values. The median of the CAA by the 6-hr RAIU values was higher 
than the median of the CAA by the 24-hr RAIU values (438.5 MBq vs. 370 
MBq). The difference between the CAA by the 6-hr and 24-hr RAIU values 
was large. 
 
The most effective IAA that must be received to treat Graves’ disease must 
be between 110 MBq and 350 MBq (EANM 2003:30). Van Isselt et al. 
(2000:609) state that the 24-hr 131I RAIU is most effective to determine the 
CAA. Therefore the 24-hr RAIU values were used with the CAA by the 6-hr 
RAIU values to determine if the IAA would still fall within the limits of 110-350 
MBq. The minimum value for the IAA calculated when the 24-hr RAIU values 
were used with the CAA by the 6-hr RAIU values is 238 MBq. The minimum 
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IAA for this calculation therefore falls within the recommended range of 110-
350 MBq. The maximum IAA on the other hand, is much higher than the most 
effective IAA of 985 MBq. For these Graves’ disease patients the median of 
the IAA calculated by the 24-hr RAIU values used with the CAA by the 6-hr 
RAIU values is 357.5 MBq. The conclusion that can be made if the 6-hr RAIU 
was used for the calculating the administration activity for the investigation 
group, the median of the IAA would not fall within the recommended range of 
110-350 MBq.  
 
The median of the CAA by the 6-hr RAIU values was higher than the median 
of the T4 values (438.5 MBq vs. 67.3 µg/dl). The CAA by the 6-hr RAIU 
values therefore shows a moderate negative linear relationship with the T4 
values (Pearson correlation coefficient obtained r=-0.43; Spearman 
correlation coefficient r=-0.58). The median of the CAA by the 24-hr RAIU 
values was higher than the median of the T4 values (370 MBq vs. 67.3 µg/dl). 
The CAA by the 24-hr RAIU values shows a moderate negative linear 
relationship with the T4 values (Pearson correlation coefficient obtained r=-
0.38; Spearman correlation coefficient r=-0.45).  
 
 
5.5 RECOMMENDATIONS 
 
The investigation was done retrospectively to answer the investigation 
questions stated in Chapter 1. As the investigation was done retrospectively, 
certain limitations occurred and were discussed. A recommendation can 
therefore be made for further future research to perform the investigation as a 
prospective investigation. A prospective investigation is also recommended 
with more than two RAIU time values to plot a graph to better evaluate the 
transit patterns of Graves’ disease, for example 3-hr, 6-hr, 18-hr and 24-hr 
RAIU values. Therefore the overall recommendation that can be made is to 
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repeat the investigation as a prospective study to verify and contribute to the 
validity of the investigation. 
 
 
5.6 SIGNIFICANCE OF THE INVESTIGATION 
 
The results from this investigation answer the investigation questions that 
were formulated to find ways to reduce the cost in the SAHS. The 
hospitalisation cost, as well as the patient cost, can be reduced if a 6-hr RAIU 
value alone can be used to calculate the 131I theraphy dosage for Graves’ 
disease. The goal with the administration of 131I therapy dosage is to treat the 
patient with Graves’ disease so that the patient’s thyroid function reaches a 
euthyroid state (ideal state). A too high dosage can cause the patient to 
become hypothyroid and to start taking thyroid medication. The accuracy with 
which the 131I therapy dosage is therefore calculated can contribute to the 
question if a Graves’ disease patient will be euthyroid or hypothyroid after 
radiation therapy. The overall implication of the investigation can therefore 
contribute to the well-being of the patient and justify the cost spent on the 
diagnosis and treatment of the Graves’ disease patient. 
 
 
5.7 SUMMATIVE PERSPECTIVE OF THE INVESTIGATION 
 
The investigation that was undertaken mainly concentrated on the transit 
patterns of the 6-hr and 24-hr 131I RAIU values in Graves’ disease patients. 
The motivation for the investigation was to find a way to reduce health care 
cost at the UNMD. By utilising only a 6-hr 131I RAIU value to calculate the 131I 
therapeutic dosage of a Graves’ disease patient, no overnight stay in hospital 
would be needed. 
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Hayes et al. (1990:519) state that the 24-hr 131I RAIU value can be discarded 
and only a 6-hr 131I RAIU value is needed to calculate the 131I therapeutic 
dosage. On the other hand, Braunwald et al. (1987:1736) also state that the 
24-hr RAIU value is traditionally used to calculate the 131I therapeutic dosage. 
The highest RAIU value is the best to calculate the therapeutic dosage as this 
gives a true reflection of the thyroid function of a Graves’ disease patient. In 
the investigation group the median of the 24-hr 131I RAIU values was higher 
than the 6-hr 131I RAIU values. The research thus showed that the 24-hr 131I 
RAIU in most of the investigation group was the highest value and most 
effective to calculate the 131I therapeutic dosage. 
 
There is an increased T4, 6-hr and 24-hr 131I value in a patient with Graves’ 
disease (Braunwald et al. 1987:1744). A correlation was done between the T4 
value and the 6-hr and 24-hr 131I RAIU value to see if there is any relation 
between these values. The investigation found no statistical significant 
relationship between the T4 values and the 6-hr and 24-hr 131I RAIU values. 
 
The recommended range of IAA that should be received to effectively treat 
Graves’ disease should be between 110 MBq and 350 MBq (EANM 2003:30). 
The investigation group would receive IAA higher than 350 MBq when the 
CAA by the 6-hr 131I values is used with the 24-hr RAIU values to calculate 
the IAA. 
 
The investigation had the advantage of justifying the cost spent by the patient 
staying overnight for the 24-hr 131I RAIU value.  In the next section the 
conclusion of the research will be discussed. 
 
 
 
 
 79 
5.8 CONCLUSION 
 
A retrospective investigation of 124 patients with Graves’ disease was 
undertaken and mainly concentrated on finding ways to reduce cost in the 
UNMD. The area that was focused on at the UNMD was the 6-hr and 24-hr 
RAIU values in patients with Graves’ disease. An analysis of the transit 
patterns was done and it was found that in most of the investigation group the 
24-hr 131I RAIU value was higher than the 6-hr 131I RAIU value.  
 
The IAA received by a Graves’ disease patient should fall within the 
recommended range of 110 MBq to 350 MBq. A 5% value difference between 
the 6-hr and 24-hr RAIU values would make a less than 1 MBq difference to 
the CAA for the Graves’ disease patient as long as the aimed IAA stayed the 
same. At the UNMD a 5% value difference between the 6-hr and 24-hr RAIU 
values would be acceptable, as the patient radiation dosage received would 
not be significantly higher. In 113 of the Graves’ disease patients the value 
difference between the 6-hr and 24-hr 131I RAIU was more than 5%. Hence, 
91.1% (n=113) had a more that 5% value difference between the 6-hr and 24-
hr 131I RAIU value.  
 
The conclusion was made that the 24-hr 131I RAIU value was more effective 
than the 6-hr 131I RAIU value in calculating the accurate therapeutic dosage in 
most of the investigation group (not all) as it indicated the highest point 
(percentage) of 131I thyroid uptake. The 24-hr 131I RAIU was found to be the 
most effective to determine the CAA. This contradicts the findings by Hayes 
et al. (1990:519). 
 
The 6-hr and 24-hr 131I RAIU values were also compared with the T4 thyroid 
diagnostic test. The conclusion that was made was that there was a moderate 
positive linear relationship between the T4 values and the 6-hr 131I RAIU 
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values, but a weak positive relationship between T4 and the 24-hr 131I RAIU 
values in Graves’ disease patients. 
 
The 131I intrathyroid treatment dosage received determines what the outcome 
of a Graves’ disease patient will be. The median of the IAA calculated by the 
administration activity of the 6-hr 131I RAIU values with the 24-hr 131I RAIU 
value did not fall within the limits of 110-350 MBq. The conclusion that was 
drawn from this investigation was that the 24-hr 131I RAIU value is more 
effective to determine the 131I therapy dosage for Graves’ disease.  
 
The transit patterns of the 131I RAIU was abnormally rapid in only 11% (n=14) 
of the Graves’ disease patients. The 6-hr RAIU values were higher than the 
24-hr 131I RAIU values. In summary, it is concluded that - according to the 
investigation done at the UNMD - the transit pattern shows that the 24-hr 131I 
RAIU value is more accurate to determine the CAA. At a time when research-
based practice is taking on an important role, it is essential for nuclear 
medicine departments to make evidence-based recommendations. The 
investigation into the correlation between the 6-hr and 24-hr RAIU clearly 
justified the cost spent on Graves’ disease patients that must stay overnight 
for the 24-hr 131I RAIU procedure. It should also be remembered that the 
higher the measurement of the 131I RAIU value the lower the therapeutic 
dosage needed, thus cost saving in its own right. 
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APPENDIX A 
 
DATA SHEETS 
 
1. Patient 131I uptake percentages and biochemistry 
information (numbers missing are patients that were 
excluded from the investigation group) 
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PATIENT 
STUDY 
NUMBER 
PATIENT 
HOSPITAL 
NUMBER 
6-HR  
131I UP-
TAKE (%) 
24-HR  
131I  
UP- 
TAKE  
(%) 
T4 TSH 99mTC- 
PERTECH-
NETATE  
THYROID  
SCAN  
( 
INCREAS-
ED OR  
DECREAS-
ED) 
1 
 
UM321825 
530503 
79 90 
 
109.0 
 
   0.01  
2 
 
UM326493 
630909 
90 97 
 
150 <0.01  
4 
 
UM321390 
550625 
69 67 153 
 
<0.01  
5 
 
UM210826 
890930 
32 59 33 <0.01  
6 
 
UM323198 
650529 
82 95,6 
 
54.7 <0.01  
7 
 
UM322491 
560918 
31 55 37.4 
 
<0.01  
8 
 
UM322694 
740901 
74 76 42.4 
 
<0.01  
10 
 
UM323897 
670927 
85 95 135.9 
 
<0.01  
11 
 
UM049979 
510523 
48 65,5 37 <0.01  
12 
 
UM324847 
730407 
75,7 80 58.7 
 
0.00  
13 
 
UM109632 
610706 
55,9 75,6 47.4 <0.01  
15 
 
UM324708 
891219 
65 60 73.9 
 
<0.01  
16 
 
UM326348 
521020 
59 67 53.4 <0.01  
17 
 
UM326628 
620425 
22 44 30.8 
 
<0.01  
 89 
22 
 
UM328554 
740320 
83 79 145.8 <0.01  
23 
 
UM328615 
651201 
78 86 
 
102.5 
 
<0.01  
24 
 
UM328553 
810219 
74 84 
 
71.9 <0.01  
26 
 
UM328598 
720206 
68 84 154.8 
 
<0.01  
27 
 
UM329201 
820103 
78 86 
 
121.6 
 
<0.01  
29 
 
UM329172 
751225 
 
49 76 
 
72.2 
 
<0.01  
31 
 
UM331115 
780616 
55 63,5 
 
67.5 
 
0.055  
32 
 
UM330652 
561012 
61,7 74,5 
 
46 
 
0.03  
33 
 
UM304837 
610927 
58 78 
 
52 
 
<0.01  
34 
 
UM332017 
291229 
31 43 31 0.01  
 36 
 
UM332201 
451129 
55 80 50 <0.01  
37 
 
UM270611 
550322 
37,3 70,4 60 
 
<0.01  
41 
 
UM333093 
540310 
57,7 77,7 73.3 
 
<0.01  
42 
 
UM334716 
591201 
72 91 77 
 
<0.03  
49 
 
UM335951 
420810 
50 70 63.2 
 
<0.01  
50 
 
UM330657 
791205 
15 40 59.2 
 
<0.01  
51 
 
UM336765 
520714 
92,3 98 37 
 
<0.01  
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52 
 
UM336960 
690914 
75 96,5 
 
154.8 
 
0.01  
53 
 
UM337405 
620824 
50 74 53.2 
 
0.43  
54 
 
UM337310 
710813 
57 67 55 
 
<0.02  
55 
 
UM336754 
660529 
55,7 70 45.3 
 
<0.01  
56 
 
UM338415 
531020 
61 80 60.5 
 
<0.01  
57 
 
UM339695 
840704 
80 87 113.8 
 
<0.01  
58 
 
UM339830 
640525 
87 86 114.0 <0.01  
59 
 
UM226136 
700629 
72 93 135.8 
 
<0.01  
62 
 
UM341553 
691008 
86 80 42.6 <0.03  
64 
 
UM343576 
660112 
52 79 131 <0.01  
65 
 
UM344221 
740330 
72,9 77 154.8 
 
<0.01  
67 
 
UM315130 
721215 
25,8 41,4 36.3 <0.01  
68 
 
UM342428 
691015 
79,4 64,5 154 
 
<0.01  
69 
 
UM342428 
420604 
50,2 74 67 
 
<0.01  
70 
 
UM345534 
570522 
74 82 78 <0.01  
72 
 
UM343608 
700128 
78 87 70 
 
<0.01  
75 
 
UM343605 
601023 
79 92 26 <0.01  
77 
 
UM176724 
550710 
49 76 43.1 0.01  
78 
 
UM343002 
550122 
73 88 62 <0.01  
79 
 
UM328615 
651201 
56 66 47 
 
<0.01  
80 
 
UM351211 
570502 
56 96 74 
 
<0.01  
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83 
 
UM351909 
710415 
18 39 15.0 <0.01  
85 
 
UM354052 
510906 
58 73 59.6 <0.01  
86 
 
UM067246 
841029 
74 59,5 149.7 
 
<0.01  
87 
 
UM336754 
660529 
55,7 70 45.3 <0.01  
88 
 
UM353714 
840216 
61 96 163.14 
 
<0.03  
90 
 
UM356740 
521107 
74 81 59 <0.01  
91 
 
UM357892 
780505 
99 100 72.5 <0.01  
94 
 
UM351536 
550624 
70 68 154.8 <0.01  
96 
 
UM360149 
600315 
73 93 76.8 <0.03  
      98  
 
UM359929 
700907 
60 68 63 <0.01  
99 
 
UM362578 
691105 
96 89 115 
 
<0.01  
100 
 
UM362527 
550726 
35 51 45.8 
 
<0.01  
101 
 
UM288586 
640818 
25 40 41.8 
 
<0.01  
102 
 
UM364785 
580412 
89 97 154 
 
0.01  
103 
 
UM234979 
630409 
72 85 74 0.01  
105 
 
UM339836 
640525 
48 66 51.4 
 
<0.01  
106 
 
UM364217 
880111 
51 78 60 
 
<0.01  
107 
 
UM342105 
770128 
41,9 63 54.2 <0.01  
108 
 
UM335307 
660505 
56,7 69 56.6 <0.01  
109 
 
UM367708 
610424 
80 84 146.0 <0.01  
110 
 
UM367382 
790813 
82 84 77.2 <0.03  
111 
 
UM368464 
710309 
80 90 71.7 
 
<0.01  
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112 
 
UM368475 
671231 
77 82,9 54.8 <0.01  
113 
 
UM336839 
671119 
50 71,9 39.1 
 
<0.01  
116 
 
UM368578 
580211 
77 88 42.1 
 
<0.01  
118 
 
UM369229 
680808 
84 85 155.0 <0.01  
119 
 
UM369194 
710215 
63 79 79.3 
 
<0.01  
121 
 
UM364098 
541130 
65 94 53.8 <0.03  
124 
 
UM864859 
681002 
63 81 
 
82.2 
 
0.01  
125 
 
UM372113 
420101 
46 63 33 
 
<0.01  
126 
 
UM364841 
521027 
78 83 77 
 
<0.01  
127 
 
UM373232 
600101 
84 73 77 
 
<0.03  
129 
 
UM373375 
880623 
82 89 72 
 
<0.01  
130 
 
UM372935 
561220 
72 95 76.1 
 
<0.03  
133 
 
UM315902 
431113 
43 57 28.6 <0.01  
134 
 
UM375892 
600405 
60 81 30.9 <0.01  
135 
 
UM375922 
670702 
71 80 42.8 
 
<0.01  
136 
 
UM374247 
691120 
84 83 154.8 
 
<0.01  
 137 
 
UM307324 
580228 
81 84 145 <0.01  
138 
 
UM378119 
441220 
34 79 
 
39 0.01  
141 
 
UM368463 
750526 
31 69 44.3 <0.01  
142 
 
UM378673 
890703 
42 66 52 <0.01  
143 
  
UM380026 
750314 
45,1 80,7 90 <0.01  
 93 
 
144 
 
UM379591 
331023 
96 92 88 
 
<0.01  
145 
 
UM379543 
550815 
35 44 97.8 0.01  
147 
 
UM380489 
530403 
76 88 71 
 
<0.01  
148 
 
UM380661 
630128 
67 80 67.1 
 
<0.03  
149 
 
UM379929 
570719 
76 87 22.1 
 
<0.01  
150 
 
UM382201 
661013 
89 97 93 
 
<0.01  
151 
 
UM382228 
561204 
26 44 24 
 
<0.01  
152 
 
UM381542 
620130 
53 69 122.5 
 
<0.01  
153 
 
UM383118 
720317 
85,5 84,7 
 
154 
 
<0.01  
154 
 
UM325613 
800916 
68 86 61 
 
<0.01  
155 
 
UM383824 
821226 
65 79 154 
 
<0.01  
158 
 
UM384020 
560221 
69 83 66 
 
 
<0.01  
159 
 
UM380598 
680522 
11,9 39,6 19.8 <0.01  
161 
 
UM385424 
830806 
82 89 154 
 
 
<0.01  
162 
 
UM386007 
770301 
56 77 
 
69 
 
<0.01  
163 
 
UM377005 
760703 
82 89 
 
77.2 
 
<0.03  
164 
 
UM386591 
791201 
82 100 77 
 
 
<0.01  
165 
 
UM386592 
890825 
76 75 154.8 
 
 
<0.01  
 94 
166 
 
UM382397 
581203 
60 79 23.6 
 
 
<0.01  
168 
 
UM384292 
821115 
77 90 110 
 
<0.01  
169 
 
UM358122 
730924 
54 68 28 
 
 
0.01  
171 
 
UM388630 
870601 
73 80 49.3 
 
<0.01  
172 
 
UM388673 
670327 
61 85 63.6 <0.01  
173 
 
UM388675 
720814 
65 78 124.7 
 
<0.01  
174 
 
UM388059 
801109 
32 45 
 
24.0 
 
<0.01  
175 
 
UM389145 
770908 
72 84 93.2 
 
<0.01  
176 
 
UM389157 
821014 
83 84 78.5 
 
<0.01  
177 
 
UM056242 
620515 
42 81 57.5 
 
<0.01  
178 
 
UM389148 
661213 
87 91 120.3 
 
 
<0.01  
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2. Patient information form 
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PATIENT 
STUDY 
NUMBER 
PATIENT 
HOSPITAL 
NUMBER 
AGE GENDER RACE 
1 
 
UM321825 
530503 
51 F W 
2 
 
UM326493 
630909 
41 F B 
3 
 
UM321679 
611219 
43 
 
F B 
4 
 
UM321390 
550625 
49 F B 
5 
 
UM210826 
890930 
15 F W 
6 
 
UM323198 
650529 
39 F B 
7 
 
   UM322491 
560918 
48 F B 
8 
 
   UM322694 
740901 
30 F B 
9 
 
   UM322478 
780412 
26 F B 
10 
 
UM323897 
670927 
37 F B 
11 
 
   UM049979 
510523 
53 F W 
12 
 
UM324847 
730407 
31 F W 
13 
 
UM109632 
610706 
43 F W 
 
 
14 
 
UM324793 
620808 
42 F B 
15 
 
   UM324708 
891219 
15 F W 
16 
 
UM326348 
521020 
52 F B 
17 
 
   UM326628 
620425 
42 F C 
18 
 
UM327301 
740815 
30 F B 
19 
 
   UM327795 
710507 
33 F B 
 97 
20 
 
   UM294443 
800710 
24 F B 
21 
 
UM326265 
470626 
57 F W 
22 
 
UM328554 
740320 
30 F W 
23 
 
   UM328615 
651201 
39 F B 
24 
 
UM328553 
810219 
23 F B 
25 
 
UM259758 
681209 
36 F B 
26 
 
   UM328598 
720206 
32 F B 
27 
 
UM329201 
820103 
22 F B 
28 
 
UM327913 
400210 
64 F B 
29 
 
UM329172 
751225 
 
29 F B 
30 
 
UM070867 
740409 
30 F B 
31 
 
UM331115 
780616 
26 M W 
32 
 
   UM330652 
561012 
48 F B 
33 
 
UM304837 
610927 
43 F B 
34 
 
   UM332017 
291229 
75 F W 
35 
 
   UM331943 
690601 
35 F B 
36 
 
UM332201 
451129 
59 F B 
37 
 
UM270611 
550322 
49 F B 
38 
 
UM291739 
580907 
46 F B 
39 
 
UM331716 
660516 
38 F B 
40 
 
UM332733 
651225 
39 F B 
41 UM333093 50 F B 
 98 
 540310 
42 
 
   UM334716 
591201 
45 M B 
43 
 
UM334202 
680508 
36 F W 
44 
 
UM310877 
560325 
48 F B 
45 
 
UM072715 
481031 
56 F B 
46 
 
UM335307 
660505 
38 F B 
47 
 
UM335768 
440310 
60 F B 
48 
 
UM335473 
630724 
41 F B 
49 
 
UM335951 
420810 
62 F W 
50 
 
UM330657 
791205 
25 F B 
51 
 
UM336765 
520714 
52 F B 
52 
 
UM336960 
690914 
35 F B 
53 
 
UM337405 
620824 
42 F B 
54 
 
UM337310 
710813 
33 F B 
55 
 
UM336754 
660529 
38 F B 
56 
 
UM338415 
531020 
51 F B 
57 
 
UM339695 
840704 
20 F B 
58 
 
UM339830 
640525 
 
40 F B 
59 
 
UM226136 
700629 
34 F B 
60 
 
UM339712 
670604 
37 F B 
61 
 
   UM336647 
730721 
31 F B 
62 
 
   UM341553 
691008 
35 F C 
 99 
63 
 
   UM286958 
410729 
63 F W 
64 
 
UM343576 
660112 
38 F B 
65 
 
   UM344221 
740330 
30 F W 
66 
 
UM189492 
600125 
44 F B 
67 
 
UM315130 
721215 
33 F B 
68 
 
   UM342428 
691015 
35 M B 
69 
 
UM344748 
420604 
62 F B 
70 
 
UM345534 
570522 
47 F W 
71 
 
   UM345969 
250304 
 
79 M W 
72 
 
   UM343608 
700128 
34 F B 
73 
 
   UM346380 
360312 
68 F B 
74 
 
UM347526 
650425 
39 F C 
75 
 
   UM343605 
601023 
44 M B 
76 
 
UM348743 
500101 
54 F B 
77 
 
UM176724 
550710 
49 F C 
78 
 
   UM343002 
550122 
49 F B 
79 
 
   UM328615 
651201 
39 F B 
80 
 
   UM351211 
570502 
47 F B 
81 
 
UM352210 
670409 
37 F B 
82 
 
UM352187 
461111 
58 F B 
83 
 
   UM351909 
710415 
33 F C 
84    UM353438 54 F W 
 100 
 510409 
85 
 
   UM354052 
510906 
54 F B 
86 
 
UM067246 
841029 
21 M W 
87 
 
UM336754 
660529 
39 F B 
88 
 
UM353714 
840216 
21 F B 
89 
 
UM356411 
520315 
53 F B 
90 
 
UM356740 
521107 
53 F W 
91 
 
   UM357892 
780505 
27 F B 
92 
 
UM358122 
730924 
32 M B 
93 
 
UM124769 
261119 
79 F W 
94 
 
UM351536 
550624 
50 M B 
95 
 
   UM360513 
640102 
41 F B 
96 
 
UM360149 
600315 
45 F B 
97 
 
   UM336736 
630819 
42 F B 
98 
 
   UM359929 
700907 
35 F B 
99 
 
   UM362578 
691105 
36 F C 
100 
 
UM362527 
550726 
50 M W 
101 
 
   UM288586 
640818 
41 M W 
102 
 
   UM364785 
580412 
47 F W 
103 
 
   UM234979 
630409 
42 F B 
104 
 
UM360009 
401230 
65 F W 
105 
 
   UM339836 
640525 
41 F B 
106    UM364217 17 F B 
 101 
 880111 
107 
 
UM342105 
770128 
28 F W 
108 
 
   UM335307 
660505 
39 F B 
109 
 
UM367708 
610424 
44 F B 
110 
 
UM367382 
790813 
26 F B 
111 
 
UM368464 
710309 
34 F B 
112 
 
UM368475 
671231 
38 M B 
113 
 
UM336839 
671119 
38 F W 
114 
 
UM365294 
510709 
54 F C 
115 
 
   UM367966 
310319 
74 M W 
116 
 
UM368578 
580211 
47 F B 
117 
 
UM368815 
770805 
28 F B 
118 
 
UM369229 
680808 
37 F B 
119 
 
UM369194 
710215 
34 F B 
120 
 
UM369258 
680821 
37 M W 
121 
 
   UM364098 
541130 
51 M B 
122 
 
UM369947 
650524 
40 F C 
123 
 
UM186157 
731120 
32 F W 
124 
 
UM864859 
681002 
37 M B 
125 
 
UM372113 
420101 
63 F W 
126 
 
UM364841 
521027 
53 F B 
127 
 
UM373232 
600101 
45 F B 
128 UM372125 63 F B 
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 420218 
129 
 
UM373375 
880623 
17 F B 
130 
 
   UM372935 
561220 
49 F B 
131 
 
UM222312 
240507 
81 F W 
132 
 
UM356462 
790101 
26 F B 
133 
 
UM315902 
431113 
62 M W 
134 
 
   UM375892 
600405 
45 F B 
135 
 
UM375922 
670702 
38 F C 
136 
 
UM374247 
691120 
36 F B 
137 
 
   UM307324 
580228 
47 M B 
138 
 
UM378119 
441220 
61 F B 
139 
 
UM375999 
390802 
66 F B 
140 
 
   UM378561 
591214 
46 F B 
141 
 
UM368463 
750526 
30 F B 
142 
 
UM378673 
890703 
16 M B 
143 
 
UM380026 
750314 
30 F C 
144 
 
   UM379591 
331023 
72 F B 
145 
 
UM379543 
550815 
50 M B 
146 
 
UM380049 
760606 
29 F B 
147 
 
   UM380489 
530403 
52 F B 
148 
 
UM380661 
630128 
42 F C 
149 
 
UM379929 
570719 
48 F B 
150    UM382201 39 F C 
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 661013 
151 
 
UM382228 
561204 
49 F W 
152 
 
   UM381542 
620130 
43 F W 
153 
 
UM383118 
720317 
 
33 F B 
154 
 
UM325613 
800916 
25 M W 
155 
 
UM383824 
821226 
23 F B 
156 
 
UM301010 
881231 
17 M B 
157 
 
UM383887 
511108 
54 F B 
158 
 
   UM384020 
560221 
49 F W 
159 
 
UM380598 
680522 
37 F W 
160 
 
UM221884 
371223 
68 F W 
161 
 
   UM385424 
830806 
22 F B 
162 
 
UM386007 
770301 
28 M B 
163 
 
   UM377005 
760703 
29 F B 
164 
 
UM386591 
791201 
26 F B 
165 
 
   UM386592 
890825 
16 F B 
166 
 
   UM382397 
581203 
47 F B 
167 
 
UM329437 
511228 
54 F W 
168 
 
UM384292 
821115 
23 F B 
169 
 
   UM358122 
730924 
32 M B 
170 
 
   UM189492 
600125 
45 F B 
171 
 
   UM388630 
870601 
18 F W 
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172 
 
   UM388673 
670327 
38 F B 
173 
 
   UM388675 
720814 
33 F B 
174 
 
   UM388059 
801109 
25 F W 
175 
 
   UM389145 
770908 
28 F B 
176 
 
UM389157 
821014 
23 F B 
177 
 
   UM056242 
620515 
43 F B 
178 
 
   UM389148 
661213 
39 F B 
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DATA SHEETS 
 
3. Patient 6- and 24-hour therapeutic dosage information 
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PATIENT 
HOSPI-
TAL 
NUMBER 
PATIENT 
HOSPI- 
TAL 
NUMBER 
6-HR  
ADMI-
NISTERED 
ACTIVITY 
(MBq) 
24-HR 
ADMINI-
STERED 
ACTIVITY  
(MBq) 
DIFFE- 
RENCE 
BETWEEN 
ADMINI-
STERED 
ACTIVITY 
CALCULA-
TED WITH 
THE 6-HR 
AND 24-HR 
RAIU 
(MBq) 
CALCU-
LATED 
ABSORBED 
ACTIVITY  
TO 
THYROID 
WHEN 
USING 6-HR 
ADMINISTE-
RED 
ACTIVITY 
FROM RAIU 
WITH THE  
24-HR RAIU  
% 
(MBq) 
HOW  
MUCH  
MORE 
ACTIVITY 
THAN 
RECOM-
MENDED 
WITHIN  
THE  
LIMITS OF 
110 MBQ –
350 MBQ 
(MBq)  
1 
 
UM321825 
530503 
375 329 46 338 0 
2 
 
UM326493 
630909 
329 305 24 319 0 
3 
 
UM321679 
611219 
740 493 247 444 94 
4 
 
UM321390 
550625 
429 442 -13 287 0 
5 
 
UM210826 
890930 
 
925 502 423 620 270 
6 
 
UM323198 
650529 
361 310 51 345 0 
7 
 
UM322491 
560918 
955 538 417 525 175 
8 
 
UM322694 
740901 
400 390 10 304 0 
9 
 
UM322478 
780412 
277 277 0 296 0 
10 
 
UM323897 
670927 
348 312 36 331 0 
11 
 
UM049979 
510523 
617 452 165 404 54 
12 
 
UM324847 
730407 
391 370 21 313 0 
13 
 
UM109632 
610706 
530 392 138 401 51 
14 UM324793 357 344 13 307 0 
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 620808 
15 
 
UM324708 
891219 
455 493 -38 273 0 
16 
 
UM326348 
521020 
502 442 60 336 0 
17 
 
UM326628 
620425 
1346 673 673 529 242 
18 
 
UM327301 
740815 
559 462 97 358 8 
19 
 
UM327795 
710507 
846 617 229 406 56 
20 
 
UM294443 
800710 
759 477 282 470 120 
21 
 
UM326265 
470626 
1057 658 399 476 126 
22 
 
UM328554 
740320 
357 375 -18 282 0 
23 
 
UM328615 
651201 
380 344 36 327 0 
24 
 
UM328553 
810219 
400 352 48 336 0 
25 
 
UM259758 
681209 
519 423 96 363 13 
26 
 
UM328598 
720206 
435 352 83 374 24 
27 
 
UM329201 
820103 
380 344 36 327 0 
28 
 
UM327913 
400210 
779 395 384 584 234 
29 
 
UM329172 
751225 
 
604 390 214 459 109 
30 
 
UM070867 
740409 
1346 580 766 687 337 
31 
 
UM331115 
780616 
538 466 72 342 0 
32 
 
UM330652 
561012 
480 397 83 358 8 
33 
 
UM304837 
610927 
510 380 130 398 48 
34 
 
UM332017 
291229 
955 688 267 411 61 
35 
 
UM331943 
690601 
356 298 58 353 3 
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36 
 
UM332201 
451129 
 
538 370 168 430 80 
37 
 
UM270611 
550322 
794 421 373 559 209 
38 
 
UM291739 
580907 
673 455 218 438 88 
39 
 
UM331716 
660516 
 
510 390 120 388 38 
40 
 
UM332733 
651225 
580 519 61 331 0 
41 
 
UM333093 
540310 
513 381 132 399 49 
42 
 
UM334716 
591201 
411 352 59 374 24 
43 
 
UM334202 
680508 
705 455 250 458 8 
44 
 
UM310877 
560325 
0 348 - 0 0 
45 
 
UM072715 
481031 
0 538 - 0 0 
46 
 
UM335307 
660505 
0 370 - 0 0 
47 
 
UM335768 
440310 
538 455 83 350 0 
48 
 
UM335473 
630724 
604 630 -26 284 0 
49 
 
UM335951 
420810 
529 423 106 414 64 
50 
 
UM330657 
791205 
 
1973 740 1233 789 439 
51 
 
UM336765 
520714 
321 302 19 315 0 
52 
 
UM336960 
690914 
395 307 88 381 31 
53 
 
UM337405 
620824 
592 400 192 438 88 
54 
 
UM337310 
710813 
519 442 77 348 0 
55 
 
UM336754 
660529 
531 423 108 372 22 
56 UM338415 485 370 115 388 38 
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 531020 
57 
 
UM339695 
840704 
370 340 30 322 0 
58 
 
UM339830 
640525 
 
340 344 -4 292 0 
59 
 
UM226136 
700629 
411 318 93 382 32 
60 
 
UM339712 
670604 
411 370 41 329 0 
61 
 
UM336647 
730721 
298 296 2 298 0 
62 
 
UM341553 
691008 
344 370 -26 275 0 
63 
 
UM286958 
410729 
779 470 309 491 141 
64 
 
UM343576 
660112 
 
569 375 194 450 100 
65 
 
UM344221 
740330 
406 384 22 313 0 
66 
 
UM189492 
600125 
375 348 27 319 0 
67 
 
UM315130 
721215 
1147 715 432 475 125 
68 
 
UM342428 
691015 
373 459 -86 241 0 
69 
 
UM344748 
420604 
590 400 190 437 87 
70 
 
UM345534 
570522 
400 361 39 328 0 
71 
 
UM345969 
250304 
1057 442 615 708 358 
72 
 
UM343608 
700128 
380 340 40 331 0 
73 
 
UM346380 
360312 
 
502 329 173 452 102 
74 
 
UM347526 
650425 
740 510 230 429 79 
75 
 
UM343605 
601023 
375 322 53 345 0 
76 
 
UM348743 
500101 
477 411 66 343 0 
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77 
 
UM176724 
550710 
604 390 214 459 109 
78 
 
UM343002 
550122 
 
406 336 70 357 7 
79 
 
UM328615 
651201 
529 449 80 349 0 
80 
 
UM351211 
570502 
529 308 221 508 158 
81 
 
UM352210 
670409 
740 519 221 422 72 
82 
 
UM352187 
461111 
336 311 25 319 0 
83 
 
UM351909 
710415 
1644 759 885 641 291 
84 
 
UM353438 
510409 
1345 569 776 699 349 
85 
 
UM354052 
510906 
510 406 104 372 22 
86 
 
UM067246 
841029 
400 498 -98 238 0 
87 
 
UM336754 
660529 
531 423 108 372 22 
88 
 
UM353714 
840216 
485 308 177 466 116 
89 
 
UM356411 
520315 
871 510 361 505 155 
90 
 
UM356740 
521107 
400 365 35 324 0 
91 
 
UM357892 
780505 
299 296 3 299 0 
92 
 
UM358122 
730924 
423 384 39 326 0 
93 
 
UM124769 
261119 
1021 529 492 572 222 
94 
 
UM351536 
550624 
423 435 -12 288 0 
95 
 
UM360513 
640102 
281 274 7 304 0 
96 
 
UM360149 
600315 
406 318 88 378 28 
97 
 
UM336736 
630819 
1233 740 493 493 143 
98 UM359929 493 435 58 335 0 
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 700907 
99 
 
UM362578 
691105 
308 333 -25 274 0 
100 
 
UM362527 
550726 
846 580 266 432 82 
101 
 
UM288586 
640818 
1184 740 444 474 124 
102 
 
UM364785 
580412 
333 305 28 323 0 
103 
 
UM234979 
630409 
411 348 63 349 0 
104 
 
UM360009 
401230 
493 406 87 360 10 
105 
 
UM339836 
640525 
617 449 168 407 57 
106 
 
UM364217 
880111 
580 380 200 452 102 
107 
 
UM342105 
770128 
706 470 236 445 95 
108 
 
UM335307 
660505 
522 429 93 360 10 
109 
 
UM367708 
610424 
370 352 18 311 0 
110 
 
UM367382 
790813 
361 352 9 303 0 
111 
 
UM368464 
710309 
370 329 41 333 0 
112 
 
UM368475 
671231 
384 357 27 318 0 
113 
 
UM336839 
671119 
592 412 180 426 76 
114 
 
UM365294 
510709 
1021 559 462 541 191 
115 
 
UM367966 
310319 
3288 1139 2149 855 505 
116 
 
UM368578 
580211 
384 336 48 338 0 
117 
 
UM368815 
770805 
430 318 112 400 50 
118 
 
UM369229 
680808 
352 348 4 299 0 
119 
 
UM369194 
710215 
470 375 95 372 21 
120 UM369258 477 325 152 434 84 
 112 
 680821 
121 
 
UM364098 
541130 
455 315 140 428 78 
122 
 
UM369947 
650524 
380 375 5 300 0 
123 
 
UM186157 
731120 
673 455 218 437 87 
124 
 
UM864859 
681002 
470 365 105 381 31 
125 
 
UM372113 
420101 
644 470 174 406 56 
126 
 
UM364841 
521027 
380 357 23 300 0 
127 
 
UM373232 
600101 
352 406 -54 257 0 
128 
 
UM372125 
420218 
395 312 83 375 25 
129 
 
UM373375 
880623 
362 333 29 321 0 
130 
 
UM372935 
561220 
411 312 99 391 41 
131 
 
UM222312 
240507 
560 529 31 319 0 
132 
 
UM356462 
790101 
502 435 67 341 0 
133 
 
UM315902 
431113 
688 519 169 392 42 
134 
 
UM375892 
600405 
493 365 128 399 49 
135 
 
UM375922 
670702 
417 370 47 334 0 
136 
 
UM374247 
691120 
352 357 -5 292 0 
137 
 
UM307324 
580228 
365 352 13 307 0 
138 
 
UM378119 
441220 
871 375 496 688 338 
139 
 
UM375999 
390802 
779 548 231 421 71 
140 
 
UM378561 
591214 
617 444 173 411 61 
141 
 
UM368463 
750526 
955 429 526 659 309 
142 UM378673 705 449 256 465 115 
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 890703 
143 
 
UM380026 
750314 
656 367 289 529 179 
144 
 
UM379591 
331023 
308 322 -14 283 0 
145 
 
UM379543 
550815 
846 673 173 372 22 
146 
 
UM380049 
760606 
None 336 - None None 
147 
 
UM380489 
530403 
390 336 54 343 0 
148 
 
UM380661 
630128 
442 370 72 354 4 
149 
 
UM379929 
570719 
390 340 50 339 0 
150 
 
UM382201 
661013 
333 305 28 323 0 
151 
 
UM382228 
561204 
1139 673 466 501 151 
152 
 
UM381542 
620130 
559 429 130 386 36 
153 
 
UM383118 
720317 
346 350 -4 293 0 
154 
 
UM325613 
800916 
435 344 91 374 24 
155 
 
UM383824 
821226 
455 375 80 360 10 
156 
 
UM301010 
881231 
449 349 100 381 31 
157 
 
UM383887 
511108 
705 380 325 550 200 
158 
 
UM384020 
560221 
429 357 72 356 6 
159 
 
UM380598 
680522 
2487 748 1739 985 635 
160 
 
UM221884 
371223 
1410 925 482 451 101 
161 
 
UM385424 
830806 
361 333 28 321 0 
162 
 
UM386007 
770301 
529 384 145 407 57 
163 
 
UM377005 
760703 
361 333 28 321 0 
164 UM386591 361 296 65 361 11 
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165 
 
UM386592 
890825 
390 395 -5 293 0 
166 
 
UM382397 
581203 
493 375 118 392 42 
167 
 
UM329437 
511228 
1139 538 601 627 277 
168 
 
UM384292 
821115 
384 329 55 346 0 
169 
 
UM358122 
730924 
548 435 113 373 23 
170 
 
UM189492 
600125 
493 384 109 380 30 
171 
 
UM388630 
870601 
406 370 36 325 0 
172 
 
UM388673 
670327 
485 348 137 412 62 
173 
 
UM388675 
720814 
455 380 75 355 5 
174 
 
UM388059 
801109 
925 658 267 416 66 
175 
 
UM389145 
770908 
411 352 59 345 0 
176 
 
UM389157 
821014 
357 352 5 300 0 
177 
 
UM056242 
620515 
705 365 340 571 221 
178 
 
UM389148 
661213 
340 352 -12 309 0 
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MEASUREMENT 
 
4. Example of 131I percentage form 
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APPENDIX C 
 
ADDITIONAL INFORMATION 
 
5.     Table summary of  the medication used by the 178 
Graves’ disease patients and if it had an influence on 
thyroid function 
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Medication name Medication group Influence on thyroid 
function (Yes/No) 
Amikacin Aminoglycosides No 
Amoxycillin Penicillins No 
Aqueous cream  Emollients  
and protectants 
No 
Aspirin  Salicylic acid  
and derivatives 
No 
Atenolol Beta-blocking agents Yes 
Betaine hydrochloride Mineral substitutes No 
Budesonide Corticosteroids No 
Calcium carbonate Calcium compounds No 
Captopril Angiotensin-converting 
enzyme 
No 
Carbimazole Sulphur-containing 
imidazole derivatives 
Yes 
Cefepime  Cephalosporins No 
Ciprofloxacin Quinolones No 
Collagenase clostrid Ointment No 
Dextran Blood substitutes and 
plasma fractions 
No 
Dilitiazem Benzothiazepine 
derivatives 
No 
Enalapril Angiotensin-converting 
enzyme (ACE) inhibitors 
No 
Fenoterol  Beta2-adrenoceptor 
agonists 
No 
Furosemide Diuretics No 
 118 
Hydrochlorothiazide Diuretics No 
Hydroxyzine Diphenylmethane 
derivatives 
No 
Hyoscine butylbromide Belladonna alkaloids 
semisynthetic 
No 
Isosorbride dinitrate Organic nitrates No 
Methyl salicylate Salicylic acid derivatives 
and capsicum 
No 
Nystatin Antibiotics No 
Omeprazole Proton pump inhibitors No 
Paracetamol Anlides No 
Propranolol Beta blocking agents Yes 
Resrepine Rauwalfia alkoids No 
Thiamin Vitamin B No 
Thyroxine Thyroid hormones Yes 
Verapamil Phenylalkylamine 
derivatives 
No 
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ADDITIONAL INFORMATION  
 
6. Summary of medications that can interfere with RAIU 
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AMIKACIN 
Group:  
Amikacin belongs to the group aminoglycosides (Gibbon 1997:262). 
Indications:  
Amikacin is used as part of the anti-infectives and antibacterials for systemic 
purposes and has already been used in medical practice for many years 
(Gibbon 1997:262). Amikacin has demonstrated outstanding lack of 
resistance problems, partly due to its resistance to the aminoglycoside-
inactivating enzymes to which other aminoglycosides are more vulnerable. 
Gibbon (1997:262) recommends that amikacin only be used in situations 
where resistance to gentamicin and tobramycin presents a problem. Amikacin 
can play an important role in the management of infections caused by gram-
negative bacilli that is resistant to drugs such as gentamicin and to bromycin 
(Berkow 1992:36). 
Pharmacokinetics: 
Quickly and entirely absorbed from the injection sites and dispersed to 
extracellular fluid and body tissues; high concentrations found in urine and 
highly perfused organs (Gibbon 1997:263). Diffusion into the cerebrospinal 
fluid (CSF) is poor even when the meninges are inflamed. 
Half-life (elimination): Usually two to three hours, except in the cases of renal 
impairment and in neonates that can prolong its elimination. 
Adverse effects: 
The following adverse effects may occur from the use of amikacin: 
 Nephrotoxicity (Gibbon 1997:263).  
 Ototoxicity. 
 Deterioration of renal function. 
 Damage to the eighth cranial nerve, characterised by dizziness, 
nystagmus, vertigo and ataxia. 
 Cochlear toxicity resulting in hearing loss. 
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 CNS adverse effects include neuromuscular blockade, headache, 
tremor, lethargy and sometimes organic brain syndrome. 
 Other adverse effects that can occur include blood dyscrasias, 
electrolyte disturbances, hepatic damage, rashes, urticaria and fever. 
Conclusion: 
Amikacin therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used amikacin during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
AMOXYCILLIN 
Group: 
Amoxycillin belongs to the group of penicillins with an extended spectrum 
(Gibbon 1997:249). 
Indications: 
Amoxycillin is used as part of the anti-infectives and antibacterials for 
systemic purposes (Gibbon 1997:249). An important characteristic of 
amoxycillin is its broad-spectrum activity against a number of Gram-positive, 
Gram-negative cocci and bacilli. Amoxycillin is used for infections of the 
respiratory tract, GIT, urinary tract, soft tissue infections, as well as for 
cholecystitis and typhoid. 
Pharmacokinetics: 
Amoxycillin when taken orally is absorbed 85% and penetrates well into most 
body fluids (Gibbon 1997:250). It is metabolised in the liver and elimination 
mainly be renal tubular secretion. 
Half-life: In the case of renal impairment prolonged, but usually 1-1.3 hours. 
Adverse effects: 
The following adverse effects may occur from the use of amoxycillin: 
 Skin rash 
 Diarrhoea 
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 Gastrointestinal irritation. 
Conclusion: 
Amoxycillin therefore has no characteristics that affect the uptake of 131I by 
the thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used amoxycillin during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
AQUEOUS CREAM  
Group: 
Aqueous cream belongs to the group of soft paraffin and fat products 
classified under emollients and protectants (Gibbon 1997:163).  
Indications: 
Aqueous cream is used to rehydrate and soothe the skin, especially in 
conditions of dryness, scaling and cracking of skin (Gibbon 1997:163). 
Pharmacokinetics: 
Emulsifying ointment 30 g, phenoxyethanol 1 g, purified water 69 g (Gibbon 
1997:164). 
Adverse effects: 
Aqueous cream has no adverse effects. 
Conclusion: 
Aqueous cream therefore has no characteristics that affect the uptake of 131I 
by the thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients 
that used aqueous cream during the 6- and 24-hr 131I RAIU examination need 
not to be excluded from the study group. 
 
ASPIRIN 
Group: 
Aspirin belongs to the group salicylic acid and derivatives classified under 
analgesics of the CNS (Gibbon 1997:368). 
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Indications: 
Aspirin is used for the following: 
  Relief from mild pain symptoms 
 Pyrexia 
 Prophylaxis of platelet aggregation 
 Rheumatic fever  
 Acute and chronic inflammatory disorders (Gibbon 1997:368). 
Pharmacokinetics: 
Aspirin is quickly hydrolysed to the active metabolite, salicylate, which is then 
bound to albumin in serum (Gibbon 1997:368). Excreted by the kidneys. 
Half-life: 15-20 minutes. 
Adverse effects: 
Aspirin may cause the following adverse effects when used: 
 Gastric irritation causing abdominal pain, vomiting, nausea and even 
occult or overt mucosal bleeding. 
 Gastric erosion and haemorrhage. 
 Pseudo-allergic reactions. 
 Tinnitus. 
 Decreased hearing. 
 Impairment of renal function. 
 Renal papillary necrosis (Gibbon 1997:368). 
Conclusion: 
Aspirin therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used aspirin during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
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ATENOLOL 
Group: 
Atenolol belongs to the group of beta blocking agents classified under beta-
blocking agents used for the cardiovascular system (Gibbon 1997:138). 
Indications: 
Atenolol is indicated for the following conditions: 
 Angina 
 Arrhythmias 
 Hypertension (Gibbon 1997:139). 
Pharmacokinetics: 
Atenolol is a lipophilic beta blocker and does not easily enter the CNS 
(Gibbon 1997:139). Excreted by the kidneys. 
Half-life: 6-9 hours. 
Adverse effects: 
The following adverse effects can occur with the use of atenolol: 
  Reduction in serum HDL 
  Triglycerides increases 
 Glucose utilisation impaired 
 Bronchospasm 
 Gastrointestinal disturbances 
 Skin reactions. 
Conclusion: 
Atenolol therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used atenolol during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
BETAINE HYDROCHLORIDE 
Group: Belongs to the group of mineral substitutes (KLOREF Leaflet 1998:1). 
Indications: Indicated for hypokaemia. 
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Pharmacokinetics: Betaine hydrochloride pharmacological classification is 
electrolytes. 
Adverse effects:  
The following adverse effects can occur with the use of betaine hydrochloride: 
 Hyperkalaemia 
 Paraesthesia of the extremities 
 Muscle weakness 
 Paralysis 
 Hypotension 
 Cardiac arrhythmias. 
Conclusion: 
Betaine hydrochloride therefore has no characteristics that affect the uptake 
of 131I by the thyroid gland during the 6- and 24-hr 131I RAIU examination. 
Patients that used betaine hydrochloride during the 6- and 24-hr 131I RAIU 
examination need not be excluded from the study group. 
 
BUDESONIDE 
Group: 
Budesonide is classified under corticosteroids for local use (Gibbon 1997:61). 
Indications: 
Budesonide is used for inflammatory conditions in the case of ulcerative 
colitis or Crohn’s colitis (Gibbon 1997:60). 
Pharmacokinetics: 
Retention enema 3 mg and sodium chloride 2 mg/100ml (Gibbon 1997:61). 
Budesonide has a first-pass hepatic clearance of higher than 90% (Gibbon 
1997:60). 
Adverse effects: 
The high first-pass hepatic clearance of budesonide reduces the risk of 
systemic adverse effects (Gibbon 1997:60). 
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Conclusion: 
Budesonide therefore has no characteristics that affect the uptake of 131I by 
the thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used budesonide during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
CALCIUM CARBONATE 
Group: 
Calcium carbonate belongs to the calcium compounds group (Gibbon 
1997:37). 
Indications: 
Calcium carbonate is indicated for patients with renal failure (Gibbon 
1997:37). 
Pharmacokinetics: 
Calcium carbonate (Gibbon 1997:37). 
Adverse effects: 
The adverse effects associated with calcium carbonate include 
hypercalcaemia and ‘milk-alkali’ syndrome (Gibbon 1997:37). 
Conclusion: 
Calcium carbonate therefore has no characteristics that affect the uptake of 
131I by the thyroid gland during the 6- and 24-hr 131I RAIU examination. 
Patients that used calcium carbonate during the 6- and 24-hr 131I RAIU 
examination need not be excluded from the study group. 
 
CAPTOPRIL 
Group: 
Captopril is classified under the group of angiotensin-converting enzyme 
(ACE) inhibitors (Gibbon 1997:147).  
Indications: 
Captopril is indicated for the following medical conditions: 
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 Cardiac failure 
  Hypertension (adults) 
 Post infarction 
 Nephropathy (Gibbon 1997:147). 
Pharmacokinetics: 
Captopril’s protein binding is mainly to albumin. Captopril is to a degree 
metabolised in the liver and excreted by the renal system (Gibbon 1997:146). 
Half-life: Can be prolonged in the case of renal failure, but mostly between 
two to three hours. 
Adverse effects: 
The following adverse effects may be experienced when using Captopril: 
 Hypotension 
 Skin rashes 
  Angioneurotic oedema 
 Neutropenia, accompanied by thrombocytopenia and pancytopenia 
  Proteinuria 
 Renal failure (Gibbon 1997:147). 
Conclusion: 
Captopril therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used captopril during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
CARBIMAZOLE 
Group: 
Carbimazole belongs to the group of sulphur-containing imidazole derivatives 
that are classified under antithyroid preparations for thyroid therapy (Gibbon 
1997:234). 
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Indications: 
Carbimazole is indicated for hyperthyroidism (Gibbon 1997:234). The 
characteristics of carbimazole inhibit thyroid hormone synthesis by inhibiting 
the incorporation of iodide into tyrosine. Carbimazole also inhibits the 
coupling of iodotyrosines. 
Pharmacokinetics: 
Readily absorbed and converted into methimazole (Gibbon 1997:234). 
Carbimazole is metabolised in the liver and excreted by the renal system. 
Half-life: Between four to 14 hours. 
Adverse effects: 
The following adverse effects may be experienced when using carbimazole: 
 Pruritus 
 Skin rashes 
 Gastrointestinal disturbances 
 Headache 
 Mild arthralgia 
 Urticaria 
 Alopecia 
 Drug-induced agranulocytosis 
 Cholestatic hepatitis with jaundice 
 Blood dyscrasias 
 “Drug-fever” reactions (Gibbon 1997:235). 
Conclusion: 
Carbimazole therefore has characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used carbimazole during the 6- and 24-hr 131I RAIU examination need be 
excluded from the study group. 
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CEFEPIME  
Group: 
Cefepime belongs to the group cephalosporins (fourth generation) and is 
classified under beta-lactam antibacterials (Gibbon 1997:252).  
Indications: 
Cefepime is effective for the use against Gram-positive and Gram-negative 
infections and this also includes Ps. aeruginosa (Gibbon 1997:252). 
Pharmacokinetics: 
Broad-spectrum semisynthetic beta-lactam antibiotics (Gibbon 1997:252). 
Adverse effects: 
No adverse effects indicated for cefepime (Gibbon 1997:255). 
Conclusion: 
Cefepime therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used cefepime during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
CIPROFLOXACIN 
Group: 
Ciprofloxacin belongs to the group quinolones classified under antibacterials 
for systemic use (Gibbon 1997:267). 
Indications: 
Ciprofloxacin is indicated for the treatment of infections caused by sensitive 
organisms (Gibbon 1997:267). 
Pharmacokinetics: 
Distributed effective throughout the body especially to the bones and soft 
tissue (Gibbon 1997:267). Metabolised in the liver. Small amounts excreted in 
the bile and in the faeces. 
Half-life: Usually four to five hours and might be a little longer in the case of 
renal failure. 
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Adverse effects: 
The following adverse effects may be experienced when using ciprofloxacin: 
 Gastrointestinal disturbances such as abdominal pain, nausea, 
vomiting and diarrhoea 
 Pseudomembranous colitis 
 Central nervous system effects 
 Skin rashes 
 Urticaria 
 Pruritus 
 Vasculitis 
 Stevens-Johnson syndrome 
 Anaphylaxis 
 Raised liver enzymes 
 Hepatic necrosis 
 Interstitial nephritis 
 Blood disorders 
 Reversible arthralgia (Gibbon 1997:267). 
Conclusion: 
Ciprofloxacin therefore has no characteristics that affect the uptake of 131I by 
the thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used ciprofloxacin during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
COLLAGENASE CLOSTRID 
Group: Collagenase clostrid is an ointment (Iruxol Mono Leaflet 2001:1). 
Indications: Collagenase clostrid is mainly used for wound cleaning. 
Pharmacokinetics: Collagenase clostrid is pharmacokinetically classified as 
collagenase clostridiopeptidase. 
Adverse effects: Local irritation or a burning sensation may be experienced 
with the use of collagenase clostrid. 
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Conclusion: Collagenase clostrid therefore has no characteristics that affect 
the uptake of 131I by the thyroid gland during the 6- and 24-hr 131I RAIU 
examination. Patients that used collagenase clostrid during the 6- and 24-hr 
131I RAIU examination need not be excluded from the study group. 
 
DEXTRAN 
Group: 
Dextran belongs to the group of blood substitutes and plasma fractions and is 
a branched-chain polysaccharide (Gibbon 1997:105). 
Indications: 
Dextran is indicated for the restore of intravascular volume in the emergency 
treatment of shock (Gibbon 1997:105). Dextran is also indicated to restore 
intravascular volume impending shock resulting from burns or haemorrhage. 
Pharmacokinetics: 
Metabolised mainly in the liver and excreted by the kidneys (Gibbon 
1997:105). 
Adverse effects: 
The following adverse effects may be experienced when using dextran: 
 Antigenicity 
 Rash 
 Pruritus 
 Hypotension 
 Anaphylaxis 
 Bleeding 
 Renal failure (Gibbon 1997:105). 
Conclusion: 
Dextran therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used dextran during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
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DILTIAZEM 
Group: 
Diltiazem belongs to the group of benzothiazepine derivatives classified 
under calcium-channel blockers for the cardiovascular system (Gibbon 
1997:145). 
Indications: 
Diltiazem is indicated for the following medical conditions: 
 Angina 
 Hypertension 
 Supraventricular arrhythmias (Gibbon 1997:145). 
Pharmacokinetics: 
Diltiazem has a high first-pass hepatic metabolism (Gibbon 1997:145).  
Half-life: Four to seven hours. 
Adverse effects: 
Diltiazem may cause the following adverse effects when used: 
 Nausea 
 Gastrointestinal upset 
 Hypotension 
 Dizziness 
 Lightheadedness 
 Ankle swelling 
 Exfoliative dermatitis 
 Lupus-like syndrome 
 Gastrointestinal bleeding (Gibbon 1997:145). 
Conclusion: 
Diltiazem therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used diltiazem during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
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ENALAPRIL 
Group: 
Enalapril belongs to the group of ACE inhibitors (Class II) classified under 
agents acting on the renin angiotensin system (Gibbon 1997:147). 
Indications: 
Enalapril is indicated for hypertension (Gibbon 1997:146). 
Pharmacokinetics: 
Enalapril is an angiotensin-converting enzyme inhibitor (Gibbon 1997:146) 
and contains enalapril maleate (Gibbon 1997:147). 
Adverse effects: 
No adverse effects indicated. The initial dosage for patients at risk of first-
dosage hypotension and the elderly should be reduced to 5 mg (Gibbon 
1997:147). 
Conclusion: 
Enalapril therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used enalapril during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
FENOTEROL  
Group: 
Fenoterol belongs to the group of beta2-adrenoceptor agonists for systemic 
use and is classified under antiasthmatics of the respiratory system (Gibbon 
1997:455). 
Indications: 
Fenoterol is indicated for asthma (Gibbon 1997:452). 
Pharmacokinetics: 
Fenoterol hydrobromide (Gibbon 1997:455). 
Adverse effects: 
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No adverse effects indicated. Should only be used when needed, not on a 
regular basis (Gibbon 1997:452). 
Conclusion: 
Fenoterol therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used fenoterol during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
FUROSEMIDE 
Group: 
Furosemide belongs to the group of high-ceiling (loop) diuretics and is 
classified under diuretics for the cardiovascular system (Gibbon 1997:132).  
Indications: 
Furosemide is indicated for the following medical conditions: 
 Oedema  
 Hypertension 
 Oliguria 
 Hypercalcaemia (Gibbon 1997:132). 
Pharmacokinetics: 
Metabolised in the liver and excreted by the renal system (Gibbon 1997:133). 
Half-life: 0.5-1 hour. 
Adverse effects: 
The following adverse effects may be experienced when furosemide is taken: 
 Hypokalaemia 
 Hypomagnesaemia 
 Hyponatraemia 
 Hypocalcaemia 
 Hyperuricaemia 
 Hypochloaemic alkalosis 
 Dehydration 
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 Hypotension 
 Hypovolaemic shock 
 Gastro-intestinal disturbances 
  Transient azotaemia 
 Gout 
 Hearing impairment 
 Allergic vasculitis 
 Rash 
 Pruritus 
 Photo-sensitivity 
 Blood dyscrasias 
 Hyperglycaemia 
 Pancreatitis 
 Jaundice (Gibbon 1997:133). 
Conclusion: 
Furosemide therefore has no characteristics that affect the uptake of 131I by 
the thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used furosemide during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
HYDROCHLOROTHIAZIDE 
Group: 
Hydrochlorothiazide belongs to the group of low-ceiling diuretics (thiazides) 
and is classified under diuretics (Gibbon 1997:130). 
Indications: 
Hydrochlorothiazide is indicated for the following medical conditions: 
 Oedema 
 Hypertension 
 Cardiac failure (Gibbon 1997:130). 
Pharmacokinetics: 
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Excreted by the renal system (Gibbon 1997:130). 
Half-life: Can be as high as 15 hours. 
Adverse effects: 
The following adverse effects may be experienced when using 
hydrochlorothiazide: 
 Hypokalaemia 
 Hypochloraemic alkalosis 
 Hyponatraemia 
 Hypomagnesaemia 
 Hyperuricaemia 
 Gout 
 Diabetes 
 Increased serum calcium 
 Hypercalcaemia 
 Influences glomerular filtration rate 
 Volume depletion 
 Hypotension 
 Gastro-intestinal reactions 
 Haematological reactions 
 Pancreatitis 
 Photo-sensitivity 
 Sulphonamide-type hypersensitivity reactions (Gibbon 1997:131). 
Conclusion: 
Hydrochlorothiazide therefore has no characteristics that affect the uptake of 
131I by the thyroid gland during the 6- and 24-hr 131I RAIU examination. 
Patients that used hydrochlorothiazide during the 6- and 24-hr 131I RAIU 
examination need not be excluded from the study group. 
 
HYDROXYZINE 
Group: 
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Hydroxyzine belongs to the group of diphenylmethane derivatives and is 
classified under psycholeptics for the CNS (Gibbon 1997:408). 
Indications: 
CNS, for example anxiety (Gibbon 1997:408). 
Pharmacokinetics: 
The properties of hydroxyzine include antidopamine, antihistaminic, anxiolytic 
and hypnotic (Gibbon 1997:408). 
Adverse effects: 
No adverse effects indicated. 
Conclusion: 
Hydroxyzine therefore has no characteristics that affect the uptake of 131I by 
the thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used hydroxyzine during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
HYOSCINE BUTYLBROMIDE 
Group: 
Hyoscine butylbromide belongs to the group of belladonna alkaloids 
semisynthetic (quarternary ammonium compounds) and is classified under 
antispasmodic and anticholinergic agents and propulsives (Gibbon 1997:44). 
Indications: 
Hyoscine butykbromide is used because of the antispasmodic action on the 
gastrointestinal, biliary and genitourinary tract (Gibbon 1997:44). 
Pharmacokinetics: 
Properties similar to those of atropine (Gibbon 1997:44). 
Adverse effects: 
Adverse effects are very rarely experienced when taking hyoscine 
butylbromide, but the following may be experienced: 
 Dry mouth 
 Visual disturbances 
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 Tachycardia 
 Central nervous system effects, for example fatigue and drowsiness 
 Paradoxical stimulation 
 Excitation (Gibbon 1997:44). 
Conclusion: 
Hyoscine butylbromide therefore has no characteristics that affect the uptake 
of 131I by the thyroid gland during the 6- and 24-hr 131I RAIU examination. 
Patients that used hyoscine butylbromide during the 6- and 24-hr 131I RAIU 
examination need not be excluded from the study group. 
 
ISOSORBRIDE DINITRATE 
Group: 
Isosorbride dinitrate belongs to the group of organic nitrates and is classified 
under vasodilators used in cardiac disease (Gibbon 1997:120). 
Indications: 
Isosorbride dinitrate is indicated for the following medical conditions: 
 Congestive cardiac failure 
 Relief and prophylaxis of angina (Gibbon 1997:121). 
Pharmacokinetics: 
Metabolites less active in the urine and is excreted by the renal system 
(Gibbon 1997:21). 
Half-life: One hour. 
Adverse effects: 
The following adverse effects may be experienced when using isosorbride 
dinitrate: 
 Headache 
 Tachycardia 
 Nausea 
 Vomiting 
 Postural hypotension wit dizziness, weakness and syncope 
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 Bradycardia 
 Methaeglobinaemia 
 Blurred vision 
 Dry mouth (Gibbon 1997:21). 
Conclusion: 
Isosorbride dinitrate therefore has no characteristics that affect the uptake of 
131I by the thyroid gland during the 6- and 24-hr 131I RAIU examination. 
Patients that used isosorbride dinitrate during the 6- and 24-hr 131I RAIU 
examination need not be excluded from the study group. 
 
METHYL SALICYLATE 
Group: 
Methyl salicylate belongs to the group of preparations with salicylic acid 
derivatives and capsicum and is classified under topical products for joints 
and muscle pain (Gibbon 1997:336). 
Indications: 
Methyl salicylate is indicated for pain of the muscles and joints (Gibbon 
1997:336). 
Pharmacokinetics: 
Ointment (Gibbon 1997:336). 
Adverse effects: 
Adverse effects as for systemic agents (Gibbon 1997:336). 
Conclusion: 
Methyl salicylate therefore has no characteristics that affect the uptake of 131I 
by the thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients 
that used methyl salicylate during the 6- and 24-hr 131I RAIU examination 
need not be excluded from the study group. 
 
NYSTATIN 
Group: 
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Nystatin belongs to the group of antibiotics and is classified as antifungals for 
dermatological use (Gibbon 1997:158-159). 
Indications: 
Nystatin is mainly used for the treatment of cutaneous and mucocutaneous 
infections (Gibbon 1997:159). 
Pharmacokinetics: 
Antimyotic antibiotic (Gibbon 1997:159). 
Adverse effects: 
Sensitisation or skin irritation is the only adverse effects stated by Gibbon 
(1997:159). 
Conclusion: 
Nystatin therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used nystatin during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
OMEPRAZOLE 
Group: 
Omeprazole belongs to the group of proton pump inhibitors (Gibbon 
1997:41). 
Indications: 
Omeprazole is indicated for the following medical conditions: 
 Gastric and duodenal ulcers 
 Reflux oesophagitis 
 Zollinger-Ellison syndrome (Gibbon 1997:41). 
Pharmacokinetics: 
Absorption takes place in the small intestine and is metabolised in the liver 
(Gibbon 1997:41). Omeprazole is excreted in the urine and the faeces. 
Adverse effects: 
 141 
The adverse effects associated with the use of omeprazole is gastrointestinal 
related and include diarrhoea, nausea, flatulence and constipation (Gibbon 
1997:41). Headache and rashes can also be experienced. 
Conclusion: 
Omeprazole therefore has no characteristics that affect the uptake of 131I by 
the thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used omeprazole during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
PARACETAMOL 
Group: 
Paracetamol belongs to the group anlides and is classified under analgesics 
for the CNS (Gibbon 1997:369). 
Indications: 
Paracetamol is mainly indicated for pyrexia or mild to moderate pain (Gibbon 
1997:369). 
Pharmacokinetics: 
Half-life: One to four hours (Gibbon 1997:369). 
Paracetamol is conjugated in the liver and excreted renally. 
Adverse effects: 
The adverse effects that can occur with the use of paracetamol include the 
following: 
 Skin reactions 
 Neutropenia 
 Thrombocytopenia 
 Hepatic necrosis 
 Renal necrosis (Gibbon 1997:369). 
Conclusion: 
Paracetamol therefore has no characteristics that affect the uptake of 131I by 
the thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
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used Paracetamol during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
PROPRANOLOL 
Group: 
Propranolol is classified under beta blocking agents (Gibbon 1997:137). 
Indications: 
Propranolol is indicated for the following medical conditions: 
 Hypertension 
 Angina 
 Arrhythmia 
 Hyperthyroidism 
 Hypertrophic cardiomyopathy 
 Prevention of cyanotic spells due to Fallot’s tetralogy 
 Anxiety 
 Thyrotoxicosis 
 Tremor 
 Migraine prophylaxis (Gibbon 1997:137). 
Pharmacokinetics: 
Metabolised in the liver and eliminated in the urine and in faeces (Gibbon 
1997:137). 
Half-life: Three to six hours. 
Adverse effects: 
The adverse effects associated with the use of propranolol include: 
 Bradycardia 
 CNS effects 
 Gastrointestinal disturbances 
 Sleep disturbances 
 Bronchospasm 
 Hypotension 
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 Acute cardiac failure 
 Skin reactions 
 Nail changes 
 Alopecia 
 Transient eosinophilia (Gibbon 1997:137). 
Conclusion: 
Propranolol therefore has characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used propranolol during the 6- and 24-hr 131I RAIU examination need to be 
excluded from the study group. 
 
RESERPINE-0.25MG 
Group: 
Reserpine belongs to the group rauwalfia alkoids and is classified under 
antihypertensives (Gibbon 1997:124-125). 
Indications: 
Reserpine is indicated for mild to moderate hypertension (Gibbon 1997:124). 
Pharmacokinetics: 
Metabolised in the liver and excreted in the faeces (Gibbon 1997:124). 
Half-life: 45-168 hours. 
Adverse effects: 
The following adverse effects can occur when using reserpine: 
 Dizziness 
 Drowsiness 
 Lethargy 
 Bradycardia 
 Hypotension 
 Decreased libido 
 Nasal congestion 
 Dry mouth 
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 Headache 
 Depression 
 Fluid retention 
 Diarrhoea 
 Nausea 
 Vomiting 
 Skin rashes 
 Pruritus 
 Thrombocytopenia (Gibbon 1997:124). 
Conclusion: 
Reserpine therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used reserpine during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
THIAMIN 
Group: 
Thiamin belongs to the group of vitamin B and is classified under vitamins 
(Gibbon 1997:80-81). 
Indications: 
Thiamin is indicated for any condition where a deficiency thereof has 
occurred (Gibbon 1997:81). 
Pharmacokinetics: 
Thiamin hydrochloride (Gibbon 1997:81). 
Adverse effects: 
Thiamin has been associated with the following adverse effects when 
intravenously used: 
 Angioedema 
 Respiratory distress 
 Hypotension 
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 Vascular collapse (Gibbon 1997:81). 
Conclusion: 
Thiamin therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used thiamin during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
 
THYROXINE-0.05MG 
Group: 
T4 is also known as levothyroxine sodium (Gibbon 1997:233). 
Indications: 
T4 is indicated for hypothyroidism (Gibbon 1997:233). 
Pharmacokinetics: 
A low percentage of thyroxine is deiodinated in peripheral tissues to T3 and 
some of T4 is metabolised in the liver (Gibbon 1997:233). T4 is excreted in the 
bile. 
Half-life: Six to seven days. 
Adverse effects: 
The following adverse effects can occur when T4 is used: 
 Hyperthyroidism 
 Skin reactions (Gibbon 1997:233). 
Conclusion: 
T4 therefore has characteristics that can affect the uptake of 131I by the thyroid 
gland during the 6- and 24-hr 131I RAIU examination. Patients that used T4 
during the 6- and 24-hr 131I RAIU examination need to be excluded from the 
study group. 
 
VERAPAMIL 
Group: 
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Verapamil belongs to the group phenylalkylamine derivatives and is classified 
under calcium-channel blockers (Gibbon 1997:144). 
Indications: 
Verapamil is indicated for the following medical conditions: 
 Angina 
 Paroxysmal 
 Supraventricular arrhythmias 
 Atrial fibrillation 
 Hypertension (Gibbon 1997:144). 
Pharmacokinetics: 
Verapamil is excreted in the urine (Gibbon 1997:144).  
Half-life: Two to eight hours. 
Adverse effects: 
The following adverse effects may be experienced when using verapamil: 
 Serious cardiovascular reactions 
 Hypotension 
 Bradycardia 
 Asystole 
 Congestive heart failure 
 Pulmonary oedema 
 Elevation of the liver enzymes 
 Nausea 
 Headache 
 Dizziness 
 Fatigue 
 Facial flushing 
 Gynaecomastia 
 Gastrointestinal bleeding (Gibbon 1997:144). 
Conclusion: 
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Verapamil therefore has no characteristics that affect the uptake of 131I by the 
thyroid gland during the 6- and 24-hr 131I RAIU examination. Patients that 
used verapamil during the 6- and 24-hr 131I RAIU examination need not be 
excluded from the study group. 
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